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INTRODUCTION 
1. Human Cytomegalovirus virion structure and genome organization 
Human Cytomegalovirus (HCMV) is a member of the β-herpesviridae family that includes the 
herpesviruses of mammals, birds and reptiles [1]. Although more recently validated by genome 
sequences, historically the members of the family were classified on the basis of the virion structure, 
composed of an envelope, tegument, capsid and an inner core containing the viral genome. The virus 
envelope is composed of a double host cell-derived lipid layer and contains the viral glycoproteins 
necessary for the cellular tropism. Compared to the other members of the family, the envelope is very 
irregular and generates a viral shape whose diameter reaches up to 300 nm with an average size of 230 
nm diameter. Under the envelope is present an amorphous matrix referred as tegument. This 
compartment carries the majority of the HCMV expressed proteins plus a huge number of host species 
including proteins and nucleic acids. Several crucial viral functions are incorporated in the tegument 
including kinases, trans-activating factors and the most abundant and immunogenic protein pp65. The 
HCMV capsid is embedded in the tegument. The core of the capsid contains a tightly packed linear 
double stranded DNA genome. In line with the huge virus dimension, HCMV has the largest genome 
among its family with approximately 230 kb, 50% larger than HSV, despite the capsids of both viruses 
being roughly of the same size (110-125 nm) [1]. 
As for the other herpesviruses, genome organization reflects the common structure composed of 
unique long (UL) and unique short (US) genetic regions flanked by two sets of inverted repeats (RL, 
repeated long and RS, repeated short). Recombination phenomenon can occur among identical terminal 
and internal repeats, leading to genome isomerization. Thus, genetic material isolated from a viral 
population consists of equal amounts of four different genomic isomers pooled together [2]. 
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Fig. 1: A. Schematic representation of HCMV virion (modified from http://viralzone.expasy.org/all_by_species/180.html). 
B. Negative stained purified virion preparation analyzed through electron microscopy.  
 
While the general genomic arrangement consistent of repeated and unique sequences is conserved 
among HCMV strains, a major difference in the open reading frame (ORF) composition and 
organization can be observed among “laboratory strains” and “clinical isolates”. The latter are 
generally defined as viruses that underwent through none or limited passages in fibroblast cells before 
being clones as bacterial artificial chromosomes (BACs) and/or sequenced. On the contrary, laboratory 
strains indicate all the strains extensively passaged and adapted to growth in human fibroblasts. These 
latter have been selected for rapid replication, fast growing and high yields of produced virus. 
Consequently to the fibroblast adaptation severe genomic rearrangements occurred in these viruses. 
Both AD169 and Towne laboratory strains acquired a large deletion in a multilocus of the UL segment, 
concomitantly being replaced by duplicated RL region. An impaired tropism, tightly restricted to 
fibroblast cells only, resulted from the abrogation of several envelope glycoproteins encoded in the 
deleted segment. Due to these rearrangements, a difference in the coding potential can be observed 
between laboratory strains and clinical isolates. In particular, while the AD169, a laboratory strain 
prototype, is predicted to encode for 208 ORFs (including the repeated segments), the coding potential 
of a clinical isolate is estimated around 252 ORFs [3]. Recently, through an integrated approach that 
combines ribosome footprinting assays, high-resolution mass spectrometry and analysis of mutated 
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viruses, Stern-Ginossar and co-workers were able to identify a total of 751 translated ORFs including 
short peptides [4]. In spite of this huge coding potential, only a small subset of these proteins 
constitutes the mature virion: it has been estimated that around 50 [1,5] proteins are inserted in the 
virion, divided through the different compartments. 
 
Fig. 2: HCMV genome organization. ORFs map of conventional laboratory strain AD169 and clinical isolate. The AD169 
genome (upper) carries TRL1-14 (green arrow), UL1-132 (dark blue arrow), IRL14-1 (green arrow), IRS1 (red arrow), 
US1-36 (light blue arrow), and TRS1 (red arrow). In the clinical isolate RL1-14, (green arrow), UL1-151 (dark blue arrow), 
IRS1 (red arrow), US1-36 (light blue arrow), and TRS1 (red arrow) are present. Modified from [3]. 
 
2. Envelope glycoproteins and viral replication 
Being the modulator of viral entry, envelope glycoproteins play a key role in HCMV pathogenesis. 
Of the total number of proteins composing the virion, around 20 [1,5–7] were identified as envelope 
associated proteins. Notably, only 8 were demonstrated as essential for virus replication in vitro in 
different cell types: glycoproteins B (gB), M (gM), N (gN), L (gL), H (gH), UL128, UL130, UL131 [8]. 
All these proteins act as complexes on the viral surface. gB is an homotrimeric complex mediating 
virus attachment and fusion, involved in the first step of heparin sulfate proteoglycans (HSPG) 
tethering. The most abundant envelope glycoprotein, gM, forms an eterodimeric complex associating 
with gN that is present on the virion only as 1:10 ratio to gM. Like gB, gM:gN complex is involved in 
HSPG tethering and stabilization of virus-cell contact. The complex that has been involved in the 
fusion event is composed by the glycoprotein gH and gL. This complex is sufficient to mediate 
fibroblast infection while formation of a pentameric complex through additional binding of UL128, 
UL130 and UL131 gene products is necessary for the infection of epithelial, endothelial, 
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polymorphonuclear leukocyte and dendritic cells (DC). Indeed, the attenuated tropism observed in 
laboratory strains can be fully explained by the mutations of the UL128-UL131 locus [3,9,10].  
Various works describing the 
HCMV entry step suggest that 
the virus uses distinct cellular 
receptors, and consequently 
different entry pathways, 
depending on the target cell. 
HCMV entry consists of a 
first low specificity - high 
avidity tethering step of the 
cell surface HSPGs mediated 
by both gB and gM/gN [11,12]. The interaction with high avidity receptors has been shown to follow 
the first attachment step. A series of “post-attachment” receptors were proposed over the time, even if 
none of them completely fulfilled this role. The most accredited cellular interactors are β1 and, to a 
lesser extent, β3 integrins. Engagement of gB by these molecules induce receptors clustering and 
intracellular signaling. The entry step culminates with gH/gL mediating the fusion of viral and cellular 
membranes. While direct fusion at neutral pH has been observed in vitro in fibroblast cells [13], low pH 
dependent receptor-mediated endocytosis is required for viral entry in epithelial and endothelial cells 
[14–16]. Moreover, a recent report suggests that HCMV entry into DCs relies on macropinocytosis-like 
pathway in a cholesterol-dependent and pH-independent manner [17]. Interaction between gB and 
dendritic cell specific C-type lectin DC-SIGN (DC specific ICAM-grabbing non-integrin) has been 
indicated to have a prominent role in DCs infection [18].  
 
Fig. 3: HCMV envelope glycoprotein complexes. The proposed role of each 
complex is indicated in the respective box. Modified from [11]. 
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HCMV entry is followed by the delivery of both the tegument and DNA containing capsid into the 
cytoplasm. Tegument proteins with regulatory function dissociate from the capsid and remain in the 
cytoplasm or migrate independently in the nucleus, where they modulate cellular and viral genes 
expression. A thick layer of tegument proteins remains tightly associated with the capsid and 
contributes to the delivery of the DNA to the nucleus [19]. For the efficient delivery of HCMV DNA, 
an intact microtubular network (MT) is essential. The MT spans from cellular periphery up to the 
perinuclear MT organizing center (MTOC). HCMV moves along MT branches to reach the nuclear 
pore complex and to inject the DNA into the nucleus [19]. Viral replicative cycle starts shortly after 
with the expression of immediate early (IE) genes, that can be detected as short as 4 hour post infection 
[20–22]. During the replicative cycle, genes expression can be divided in distinct temporal phases, 
defined as immediate early, early and late, that are linked together by a tightly regulated temporal 
cascade. A set of genes expressed with immediate early kinetic, whose transcription do not require de 
novo protein synthesis, act as global regulators of viral genes expression. Early genes protein products 
are responsible for DNA replication, while late genes encode for structural proteins and are transcribed 
following viral DNA replication [19]. 
Fig. 4: Delivery of HCMV 
capsid to the nucleus. (A) 
HCMV capsid and associated 
tegument proteins are 
transported along the 
microtubules (B) toward the 
nucleus. A set of tegument 
proteins dissociate from the 
capsid and migrates 
independently to the nucleus 
(C). Viral DNA is released into 
the nucleus through the nuclear 
pores (D). Modified from [19].  
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HCMV binding and entry induces a global reprogramming of the cellular activity and causes 
profound changes in infected cell morphology. The most evident is the formation of a large 
cytoplasmic juxtanuclear region defined virion assembly complex/compartment (AC), corresponding to 
the virus final budding site. Before being released, viral particles pass through a series of maturation 
steps. DNA containing capsids exit the nucleus through a successive envelopment/de-envelopment 
process at the nuclear membrane [23,24] and reach the cytoplasm to complete their morphogenesis. At 
this stage, partial tegumented nucleocapsids reach the AC to acquire the full spectrum of tegument 
proteins and envelope glycoproteins [25]. Viral assembly complex is organized as nested cylinders of 
secretory apparatus structures, surrounded by the endoplasmic reticulum (ER) network [26,27]. Golgi 
and trans-Golgi network membranes constitute the edge of the AC, while the inner part contains 
vesicles positive for both the early and recycling endosomes markers. Secondary viral envelopment 
 
Fig. 5: HCMV maturation. The model illustrates the HCMV virion particles formation, maturation and budding 
processes. Major cellular and viral proteins involved in these processes are reported (red and blue, respectively). List of 
abbreviations: DB, dense body; VP, virus particle; EE/RE, early endosome/recycling endosome; LE, late endosome; GB, 
Golgi body; ER, endoplasmic reticulum; NP, nuclear pore; INM, inner nuclear membrane; ONM, outer nuclear 
membrane; A, B and C, types of nuclear capsids. From [23]. 
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occurs when a viral particle capture a vesicle promoting its bending and fusion around the tegumented 
nucleocapsid [28]. Vesicles containing mature enveloped HCMV virions fuse with the cellular plasma 
membrane releasing the viral particles.  
3. Pathogenesis 
Human cytomegalovirus infection is ubiquitous among adult population, ranging around 55-60% of 
the world population, although reaching peaks of more than 90% seroprevalence in given populations 
grouped according to age-gender-socioeconomic related factors [1]. Horizontal transmission can occur 
through exchange of bodily fluid at mucosal surfaces. Primary infection is generally asymptomatic in 
healthy individuals, where a strong immune response to HCMV is able to limit and contain the spread 
of the disease. Bland clinical symptoms and spontaneous acute infection resolution are associated to 
infection of immunocompetent individuals; therefore antiviral therapies are usually not indicated in 
these settings [1]. Nevertheless complete clearance of the virus by the organism is never achieved and 
lifelong lasting latency with recurrent and spontaneous viral reactivation is always observed. Viral 
replication and spread is brought under control by the combined action of both innate and adaptive 
immune responses: severe diseases, associated with HCMV infection and reactivation, occur in settings 
where immune response is severely suppressed (transplantations related immunosuppression) or 
compromised (AIDS patients). Moreover, due to the HCMV ability to cross the transplacental barrier, 
congenitally acquired infection can pose a severe treat to the fetus that lacks a fully functional immune 
system able to counteract the viral infection. Thus in the presence of an impaired or absent immune 
system, antiviral therapies are necessary to counteract the severe disease associated to the HCMV 
primary infection or reactivation. However almost all the antiviral agents actually on the market 
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showed a significant number of potential side effects including marrow and organ toxicity and 
increasing drug resistant viral strains [1].  
Passive immunization using hyperimmune globulin preparations with high levels of antibodies 
against HCMV (CMVIG) are usually implemented as prophylactic tools to reduce the morbidity and 
mortality associated to HCMV infection in immunocompromised patients. For example combination of 
antiviral drug glancicovir and CMVIG proved to be effective in preventing HCMV infection in patients 
undergoing solid organ transplant [29]. Moreover a study suggests their effectiveness in the treatment 
and prevention of severe diseases associated to congenital HCMV infection [30].  
Nevertheless, rather than a general prophylactic tool, the efficacy and effectiveness of CMVIG in 
reducing HCMV infection seems to be restricted to specific clinical cases while only modest beneficial 
effects were shown upon CMVIG treatment in other settings such as hematopoietic cell transplantation 
(HCT) and blood transfusion in premature newborns [31]. Additionally CMVIGs exhibit low potency 
in vitro [32] and must be administrated at high doses to reach the amount of neutralizing antibodies 
required to exert a beneficial effect. To increase the efficacy of a passive immunization therapy, a 
series of neutralizing monoclonal antibodies against immunodominant HCMV envelope glycoproteins 
were developed. For example, a highly in vitro neutralizing antibody against gH was isolated from the 
spleen of a CMV seropositive patient. The monoclonal antibody, named MSL-109 or sevirumab, was 
tested in phase II clinical trials as treatment for CMV-induced retinitis in AIDS patients [33]. 
Unfortunately the tests were stopped due to lack of efficacy [34].  
4. Immune response manipulation and evasion mechanisms 
Primary infection in immunocompetent individuals is accompanied by a period of viral 
dissemination (viremia). In this phase, virus excretion in bodily fluids, such as breast milk, blood, urine, 
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saliva and seminal secretions lasts from months to years depending on the host age, and is the primary 
cause of viral transmission. Drop and clearance of the acute infection phase correlates with the 
mounting of strong humoral and, more importantly, cellular adaptive immune responses. Despite the 
setting up of a strong response, a complete clearance of infected cells is never observed. HCMV is able 
to establishing lifelong latency remaining silent in myeloid lineage cells [35].  
To escape from the immune system surveillance, HCMV has developed a huge arsenal of genetic 
functions committed to alter and modulate both innate and adaptive arms of the immune response. In 
particular, HCMV coevolution within its host has led to the incorporation of a repertoire of functions 
with strong homologies to host genes. Thus the virus is able to subvert the immune system mimicking 
the same strategies and mechanisms used by hosts to clear the infection. Inhibition of complement 
cascade and natural killer (NK) cells activation, attenuation of interferon (INF) response and disruption 
of antigen presentation are only few examples of the functions hijacked by virus encoded chemokines, 
cytokine and cellular receptors homologues [35]. 
Table 1: List of selected protein functions encoded by cytomegalovirus that 
interfere with adaptive and innate immune response. Modified from [35]. 
Adaptive immune 
response 
Innate immune  
response 
Inhibits MHCI and II expression 
(US3) 
Fcγ Receptor Homologs              
(UL119, RL11) 
MHC I and II degradation           
(US2) 
Interferon-Mediated Immunity     
(IE2, UL83) 
MHC I degradation                     
(US11) 
Natural Killer Cells                         
(UL18, UL142, UL141, UL40) 
Binds MHC I molecules              
(US8, US10)  
Cytokine Homologs                     
(UL111) 
Inhibits TAP peptide transport    
(US6) 
Viral Chemokine Homologs    
(UL146, UL147, UL128-131) 
Inhibit MHC II expression         
(UL83) 
Apoptosis                                          
(UL36, UL37x1) 
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4.1. Complement cascade 
A first line of defense against viral infection resides in innate response modulators such as the 
complement system and natural killer mediated cytotoxicity. The complement system is composed of a 
multitude of serum proteins that circulate in the blood. Upon direct deposition of C3 complement 
molecule on invading microorganisms or infected cells surface (alternative pathway), a cascade of 
proteolitically events is initiated. The activation pathway usually culminates with the formation of a 
membrane attack complex (MAC) with the ability to lyse the bound microorganism or cell. 
Alternatively, complement opsonized structure can be efficiently disposed by phagocytic cells. A more 
efficiency complement activation is trigged by binding of complement protein C1 to the constant 
region (Fc) of immunoglobulin clustered by antigen binding (classical pathway). Antibodies marking 
surface exposed viral antigens on infected cells can trigger the classical complement pathway leading 
to the infected cell lysis. This mechanism is referred as antibody dependent complement mediated lysis 
(ADCML) [36]. Several molecules act as regulators of complement activation (RCA) controlling and 
assuring that the complement cascade becomes activated only when needed. Surfaced expression of 
two of these proteins, CD46 and CD55, is highly enhanced in HCMV infected cells [37]. Moreover 
CD55 and CD59 RCAs incorporation in the HCMV virion has also been reported [38]. These 
mechanisms protect both HCMV infected cells and virions from the recognition and consequently from 
the activation of the complement cascade.  
4.2. Natural killer cells 
Natural killer (NK) cells are a component of the innate immune response possessing cytotoxic 
activity. NK cells recognize and eliminate host damaged cells, such as virus infected cells, providing a 
rapid and efficient response to intracellular infections. Mechanisms regulating NK activation rely on a 
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fine balance between activating and inhibitory signals trigged by the binding to the target cells 
receptors rather than to direct recognition of the pathogen. Strong activating signals are trigged by the 
binding of NKG2D receptor to surface exposed MHC class I related proteins MICA and MICB. Fc 
portion of IgG covering the surface of a pathogen or an infected cell can be recognized by the gamma 
immunoglobulin Fc receptor IIIA (FcγRIIIA) CD16 present on NK cells surface leading to their 
activation in a mechanism called Antibody Dependent Cellular Cytotoxicity (ADCC). On the contrary, 
inhibitory signaling pathway arises from MHC class I recognition by different inhibitory receptors such 
as the Leukocyte Ig-like receptor (LIR)-1 and the CD94/NKG2 lectin-like receptors. Inhibition is 
achieved upon tyrosine phosphorylation of the immunoreceptor tyrosine-based inhibition motifs (ITIM) 
present in the cytoplasmic tails of these proteins [39–41].  
Different works have demonstrated a prominent role for NK cells in controlling HCMV infections 
both in humans and mice [1]. As expected, HCMV has evolved numerous functions that modulate and 
interfere with NK cell activity [42]. The viral protein gpUL18, a MHC class I homologue, localizes on 
infected cells plasma membrane where it binds the NK LIR inhibitory receptor [43–45]. HCMV UL40 
is able to upregulate non-classical MHC-I molecule HLA-E and to promote its efficient cell surface 
expression. HLA-E binds the inhibitory receptor CD94/NKG2A and the overall effect of its 
upregulation during HCMV infection is thought to protect the infected cells through NK cells inhibition 
[46]. Finally, the two protein products of the UL142 and UL16 genes downregulate the surface 
exposition of the NK activatory receptor ligands MICA and MICB retaining them intracellularly in the 
ER or Golgi apparatus [47–51].  
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5. Fc receptors  
Fc receptors (FcR) are cellular surface exposed proteins present on almost every kind of immune 
cell and on some epithelial, endothelial and hepatocytic cells. Fc receptors are involved in the process 
of antigen recognition but, unlike the B and T cell receptors (BCR and TCR, respectively) they do not 
directly bind the antigen: instead the Fc receptor ligands are the constant region of immunoglobulins. 
Each Ig class has one or more dedicated Fc receptors and they are named according to the type of 
bound Ig: FcR, FcγR, FcδR, FcµR and FcεR bind respectively Ig of the A, G, D, M and E class.  
The Fc receptors belong to the immunoglobulin superfamily (IgSF) and possess at least one 
immunoglobulin domain. The only exception is the FcεRII receptor that belongs to the lectin family 
and possesses a C-type Lectin Domain (CLTD). Two layers of β-sheets composed from seven to nine 
antiparallel β-strands connected by a loop compose the immunoglobulin fold common to all the 
members of the Ig superfamily [52].  
Fc receptor functions can be divided in three main categories: regulation of immune-cell responses 
through their activation or inhibition; antigen-antibodies immunocomplexes (IC) uptake; 
immunoglobulin transport and stabilization. 
Regulation of immune cells functions can be initiated through the recruitment of surface FcRs by 
antigen bound Igs. Depending on the kind of FcRs recruited and on the type of cell, activatory or 
inhibitory stimuli can be triggered. Many different downstream effects can result from the signaling 
cascade including up- or down- modulation of cellular proliferation, phagocytosis, degranulation, 
cytokine production. Most FcRs do not possess intrinsic signaling motifs thus they must associated 
with other proteins able to mediate the signals transduction. The Immunoreceptor Tyrosine-based 
Activatory or Inhibitory Motifs (ITAM and ITIM, respectively) are regulatory motifs that are present in 
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the cytoplasmic tails of the receptor or in the associated units and regulate the signaling cascade. 
Receptor engagement induces a phosphorylation event on the tyrosine present in both motifs that 
culminates with the activation, in the case of ITAM triggered signaling, or in the inhibition, in the case 
of ITIM signaling, of the cell functions [52].  
Another important function mediated by the FcRs is the immune complexes internalization. FcRs 
mediate ICs endocytosis and delivery into lysosomes for degradation. Proteolytically cleaved antigen-
derived peptides can then be loaded and presented on MHC class I and II molecules [52].   
Fig. 6: Principal functions of Fc receptors. a: Fc receptors modulate positive or negative cellular signaling upon IC 
binding. Activation can lead to cellular proliferation, phagocytosis, degranulation and is mediated by the ITAM motif 
present in the FcR associated γ-chain. By contrast, an inhibitory signaling cascade can be initiated through engagement of 
the ITIM motif possessing FcγRIIB. b: FcR can mediate both IC and Ig-coated pathogens phagocytosis. The internalization 
process can lead to the clearance of the pathogen/IC and to MHC class I and class II antigen-presentation of the resulting 
antigenic peptides. From [52]. 
 
Finally, some specialized Fc receptors have different functions based on the organism development 
stage: for example neonatal Fc receptor (FcRn) is essential for the transfer of passive humoral 
immunity from the mother to the fetus through transportation of maternal IgG across the placenta. 
Chapter 1 
16 
  
Similarly, the polymeric Ig receptor, pIgR, is present on polarized epithelia and it is responsible for 
polymeric IgA and IgM transcitosis [52]. 
Table 2: Fc receptors: structure, Fc affinity and expression profiles. From [52]. 
  
 
β2m, β2 –microglobulin; DC, dendritic cell; FcRH, Fc-receptor homologue; FcRn, neonatal Fc 
receptor; GPI, glycosylphosphatidylinositol; Ig, immunoglobulin; LC, Langerhans cell; Mr, relative 
molecular mass; ND, not determined; NF, not found in mice; NK, natural killer; poly-IgR, 
polymeric immunoglobulin receptor. 
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5.1. IgG and Fc gamma receptors 
IgG is the most abundant and most versatile immunoglobulin isotype. It is present in almost all 
extracellular fluids and in blood where it constitutes up to 75% of total serum Ig. In human, IgGs are 
divided in 4 distinct subgroups designed IgG1, IgG2, IgG3 and IgG4 that despite having around 95% 
amino acidic identity, show remarkable differences in terms of biological and physicochemical 
properties and relative abundance. IgG are monomeric glycoproteins composed of two identical longer 
polypeptides called heavy chains (H) linked by disulfide bonds to two identical shorter light chains (L). 
Disulfide bonds keep together the two heavy chains and form an “hinge region” responsible for the 
protein flexibility. Each chain is composed of structured immunoglobulin domains: four Ig domains 
(CH1, CH2, CH3 and VH) are present in the heavy chain and two domains (CL and VL) in the light chain. 
IgG fragmentation through papain protease generates two identical Fab (Fragment antigen binding) 
fragments and one Fc (Fragment crystallisable). VH and VL variable regions of the heavy and light 
chains constitute the immunoglobulin antigen binding site. IgGs have a prominent role as effectors of 
the adaptive response by protecting the organism against extracellular pathogens through binding and 
neutralization or complement activation and lysis. Moreover IgG can engage the FcγRs present on 
almost all kind of innate immune system cells activating a plethora of cellular responses that concur in 
the pathogen clearing. Thus FcγR interaction with IgG bridges the cellular and humoral immune 
responses.  
 
Fig. 7: Human IgG subclasses. Igs domains are indicated as: VL, variable light; CH, variable heavy; CH, constant heavy; 
CL, constant light. Red line, disulphide bond; rhombus, N-linked glycosylation  
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In human FcγR are divided in: FcγRI (CD64), FcγRII (CD32) composed of three isoforms A, B 
and C, and FcγRIII (CD16) divided in isoforms A and B. All of them are single pass membrane 
spanning proteins, with the exception of glycosyl-phosphatidylinositol (GPI)-linked membrane 
anchored FcγRIIIB [53,54]. Like other FcRs, FcγRs are usually protein complexes composed of an IgG 
Fc binding -chain associated to different signaling transducing homodimeric proteins called γ, β or ζ 
chains, which contain the ITAM motif in their cytoplasmic tail. The only exception is the FcγRIIIB that 
do not induce downstream signaling, and the FcγRII class, that is able to transduce the signal 
independently from the association with accessory proteins. While ITAM motif is present in the 
FcγRIIA C-terminus, the FcγRIIB is the only known ITIM containing FcR.  
FcγRI is the only high affinity receptor and is able to bind monomeric IgG with an affinity 108-109 
M
-1
, while all the others receptors show 100-1000 lower affinity. Thus, FcγRI is completely saturated 
with the ligand, but is unable to mediate signaling until antigen binding induces receptors clusterization. 
By contrast, indiscriminate activation of pro-inflammatory response by circulating monomeric IgG is 
prevented by the low affinity of the majority of FcγR. For these receptors, ICs binding induces 
receptors cross-linking allowing for the initiation of the signaling pathways. Moreover the binding 
stoichiometry of 1:1 receptor-ligand prevents accidental receptor activation [54].  
In response to a viral infection, FcγRs and specific IgGs together are able to put in place a 
coordinated series of cellular responses that involve both the innate and the adaptive arms of the 
immune system.  
Antibodies coated virions or infected cells can be readily recognized by cytotoxic cells through 
their FcγRs, leading to a strong Antibody Dependent Cellular Cytotoxicity response. Thus, the FcγR 
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present on the innate branch cells, such as NK and macrophages, can link the specificity of the humoral 
adaptive response to the potent effector function of the innate response.  
5.2. Fc receptor homologues  
Among the mechanisms used by pathogens to escape the immune system response, the acquisition 
of FcR homologues function seems to be highly diffuse. While the host cells use the FcR as a mean to 
sense and dispose of antibodies marked intruders, pathogens have developed similar functions in order 
to counteract immune system recognition. Staphylococcus aureus, a Gram positive bacterium, covers 
its membrane with the Fc binding protein A that captures and fixes immunoglobulins in the wrong 
orientation on the bacterium surface, disguising it and impairing its identification [55]. Fc binding 
proteins are highly conserved among the human herpesviruses: genes coding for FcR homologue 
functions were found almost in all genomes of the herpesviridae family suggesting a prominent role for 
these functions in pathogen survival [56]. 
Most of the viral FcRs (vFcR) recognize and bind the constant region of IgG probably impairing 
and inhibiting host effector function. Different mechanisms of action were proposed depending on the 
localization of the vFcR. Disguising mechanisms, similar to those observed for S. aureus protein A, can 
be put in place by vFcR present on the virions while circulating antibodies clearing can start from vFcR 
exposed on infected cells membrane. While the latter can inhibit the ADCC of the infected cells, the 
former can contribute to counteract the neutralization activity of antibodies bound to their target on the 
viral surface. The blockage of the free Fc portion can avoid the recognition of the viral particles and the 
activation of mechanisms such as the complement cascade or phagocytosis processes. This mechanism, 
named antibody bipolar bridging, has been described for Herpes Simplex Virus (HSV) heterodimeric 
FcR gE:gI.  
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Fig. 8: Herpesviral FcγRs mediated mechanism of protection against antiviral IgG. The Fc portion of human IgG 
bound to viral antigen on infected cell surface or on virus particle can recruit complement proteins (A) or host FcγRs (B). 
The former mechanism culminates with the complement-mediated lysis (ADCML) of the infected cells/viral particle. 
Recruitment of host FcγRs present on the surface of cytotoxic effector cells results in the antibody-dependent cellular 
cytotoxicity (ADCC). (C) Viral FcγR impairs both mechanisms through the blockage of the Fc portion of the IgG. This 
mechanism of antibody bipolar bridging protects the virus particle or infected cell from recognition and destruction. From 
[56]. 
Moreover, several reports underline the importance of the vFcγR endocytic activity of HSV, 
Pseudorabies Virus (PrV) and Varicella Zoster Virus (VZV) in the contest of the infected cells [57–60]. 
For example gE:gI vFcγR complex in PrV infected monocytes internalizes antibodies-viral antigens 
complexes from the cell surface preventing the ADCML of the infected cell [61].  
HCMV is known to encode for two different FcγRs: glycoprotein gp68, encoded from the UL118-
119 locus, and gp34, encoded from the RL11 locus [62,63]. Both gp68 and gp34 are type I membrane 
proteins with a predicted IgSF domain and extensive glycosylation and localize on the membrane of 
transfected cells. gp68 is a 347 amino acid long protein generated through a splicing event between the 
UL119 and UL118 open reading frames (ORFs). It is predicted to possess up to 12 potential N-linked 
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and several O-linked glycosylations sites. In silico alignment showed that the IgSF domain of gp68 
displays a high degree of similarity to the third IgSF domain of cellular FcγRI. Moreover an almost 
consensus ITIM motif (WSYKRL328) is present in gp68 cytoplasmic tail. Studies conducted on the 
purified ectodomain showed that gp68 binds Fcγ with a 2:1 stoichiometry. Thus a single IgG can 
crosslink two molecules of gp68 allowing receptor clusterization in the absence of antigen binding. 
Surface plasmon resonance studies demonstrated a high affinity between gp68 and Fcγ with a KD in the 
nanomolar range. Furthermore the binding remained stable at acidic pH, a major difference from the 
previous characterized gE:gI- Fcγ complex that dissociate at pH lower than neutrality [64].  
Less experimental information is available for RL11 
gene product gp34. It consists of 234 amino acids and 
possesses only N-linked glycosylations on three predicted 
sites. Multiple alignments showed the presence of 
determinants that are conserved in the Fc binding region of 
host FcγIIIRs. The cytoplasmic tail contains a predicted 
dileucine internalization motif (DXXXLL226) that could 
indicate a propensity of the protein to enter the endocytic 
route upon Fcγ binding. Differential binding propensity to 
the IgG subclasses for gp68 and gp34 are still unknown, but 
the different reported affinities for IgG from various species suggest a diverse mechanism of binding 
for the two proteins. In particular, both gp68 and gp34 were able to bind to the same levels IgG1, IgG2, 
IgG3 and IgG4 while only gp34 showed affinity for non-human IgG binding both rabbit and rat IgGs 
[62]. Moreover the HCMV FcRs seem to be diverse from HSV gE:gI not only for what concern pH 
requirement but also in terms of binding sites. In fact, while gE:gI binding site to the Fc fragment 
Fig. 9: Herpesviral Fcγ receptors. Modified 
from [56]. 
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competes with protein A, HCMV vFcγRs bound to the Fc can be immunoprecipitated with the S. 
aureus Fc binding protein. Overall the structural and topological similarities between HCMV FcγR and 
the Fc binding proteins coded by other herpesviruses may indicate a mechanism of action similar for 
these classes of proteins [56]. Nevertheless some distinctive features can evidence a mode of action that 
do not reside in the mechanisms previously described, suggesting a diverse and peculiar role for the 
HCMV FcγR in the contest of viral infection.  
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Project summary 
Human cytomegalovirus (HCMV) employs many different mechanisms to escape and subvert the host 
immune system surveillance. Among these different mechanisms the role of human IgG Fc receptors 
(FcγR) in HCMV pathogenesis is still unclear. In mammalians, FcγRs are expressed on the surface of 
all haematopoietic cells and have a multifaceted role in regulating the activity of antibodies to generate 
a well-balanced immune response. Viral proteins with Fcγ binding ability are highly diffuse among 
herpesviruses. They interfere with the host receptors functions in order to counteract immune system 
recognition. So far, two human HCMV Fcγ binding proteins have been described: UL119 and RL11. 
This work was aimed to the identification and characterization of HCMV Fcγ binding proteins. The 
study is divided in two parts: first the characterization of UL119 and RL11; second the identification 
and characterization of novel HCMV Fcγ binding proteins. Regarding the first part, we demonstrated 
that both UL119 and RL11 internalize Fcγ fragments from transfected cells surface through a clathrin 
dependent pathway. In infected cells both proteins were found in the viral assembly complex and on 
virions surface as envelope associated glycoproteins. Moreover, internalized Fcγ in infected cells do 
not undergo lysosomal degradation but rather traffic in early endosomes up to the viral assembly 
complex. Regarding the second part, we were able to identify two novels Fcγ binding protein coded by 
CMV: RL12 and RL13. The latter was also further characterized as recombinant protein in terms of 
cellular localization, Fc binding site and IgG internalization ability. Finally binding specificity of both 
RL12 and RL13 seems to be confined to human IgG1 and IgG2. Taken together, these data show that 
HCMV codes for up to 4 FcγR and that they could have a double role both on virus and on infected 
cells. 
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ABSTRACT 
Human cytomegaloviruses (HCMVs) employ many different mechanisms to escape and subvert the 
host immune system expressing proteins that mimic MHC class I molecules, chemokines and human 
IgG Fc receptors (FcRs). Among these different mechanisms the role of FcRs in HCMV pathogenesis 
is still unclear. We focused our attention on the characterization of HCMV Fc binding proteins UL119 
and RL11. In particular, we demonstrated that both proteins are able to bind human Fc fragments on 
the surface of transfected cells. This event triggers the internalization of the receptor-ligand complex 
trafficking from the cellular membrane to endosomes through a clathrin dependent pathway. 
Intriguingly, internalized IgG do not reach the lysosomal compartment, but remain localized in Rab5 
positive vesicles. Moreover, we demonstrated that both proteins are found in infected cells assembly 
complex and are present on the surface of the virions as envelope associated glycoproteins. Finally, we 
analyzed the Fcγ internalization activity of infected cells demonstrating that internalized 
immunoglobulins do not undergo lysosomal degradation but rather traffic in early endosomes EEA1 
positive vesicles up to the viral assembly complex. Taken together, these data suggest that HCMV FcR 
could have a double role both on virus and on infected cells.  
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INTRODUCTION 
Infection by Human cytomegalovirus (HCMV) occurs in the majority of population. Following 
primary infection, which generally remains asymptomatic, the virus establishes a lifelong latent 
infection persisting in precursor of dendritic and myeloid cells [1,2]. Reactivation requires 
immunosuppressive conditions and is associated to a variety of diseases [3]. Among herpesviridae, 
HCMV owns the largest genome and carries several gene products able to counteract host immune-
response. Such immune-modulatory proteins span from MHC class I and receptor homologues to 
chemokine-like and Fc receptor-mimicking molecules [4].  
Human Fc receptors (hFcRs) are present on the cell surface of most cells of myeloid and lymphoid 
origin and represent the connection between cell-mediated and humoral immune-response [5]. Immune 
cells benefit of these plasma membrane molecules as sensor of antigens or immune complexes in the 
extracellular environment. Following ligand engagement, they trigger the appropriate responses to 
infection. Several herpesviruses code for proteins able to bind the constant region of immunoglobulin 
known as viral Fc receptors (vFcRs), most of them recognize the constant fragment of IgG (Fc) and 
potentially interfere with the host Fc receptors [6,7]. IgG production in response to viral infection is a 
crucial step in activating host effector functions, including neutralization/phagocytosis processes and 
antibody-dependent cellular cytotoxicity (ADCC) [8]. Nonetheless, passive transfer of anti-HCMV IgG 
has been shown to limit viral infection and used as therapeutic agent to cure acute cytomegalovirus 
infection in human patients [9,10]. Basically three putative mechanisms of action have been envisioned 
for vFcRs: a) recruiting antibodies on the viral particles to facilitate cells internalization, b) counteract 
neutralizing antibodies via a mechanism known as “antibody bipolar bridging” [11–14] and c) clearing 
circulating IgG by capturing them on the surface of infected cells with consequent internalization and 
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lysosome targeting of the antibody [15]. The first and second hypothesis assume their localization on 
the viral particle, the third requires solely their expression in infected cells. Despite several indications 
favoring one or the other among these hypotheses, the functional role of vFcRs has never been fully 
elucidated. Furthermore, other herpesviral Fcbinding proteins, such the HSV-1 gE , the murine CMV 
m138 and the varicella-zoster virus (VZV) gE, are known to play crucial roles in in vivo infection 
independently of their antibody binding ability [16–20]. 
HCMV encodes four proteins possessing Fc ability [21–23] All of them are glycosylated type I 
membrane proteins with a predicted Ig-like domain and localize on cell surface when expressed in 
isolation. The gene products RL11, known also as gp34, and UL119, indicated as gp68, was found 
expressed at the cell surface based on flow cytometry analysis of Fc binding to unpermeabilized cells 
transduced with adenoviruses expressing gp34 or gp68 [22]. Flow cytometry analysis was also used to 
assess RL12 and RL13 plasma membrane localization and Fc binding ability in transfected cells [21]. 
The presence on purified viral particles has so far been reported for UL119 and RL13 [24,25]. Binding 
specificity versus human IgG subclasses differs among these proteins. RL11 and UL119 bind all 
human IgGs whereas RL12 and RL13 do not bind IgG3 and IgG4 [21,22].  
Irrespective of whether they have to be inserted into the viral particles or escort IgG to degradation, 
herpesviral Fc binding proteins need to be targeted to the plasma membrane and then enter the 
endocytic pathway. Among the HCMV Fc binding proteins, only RL13 has been reported to be able to 
internalize following Fc binding at plasma membrane [21]. Endocytosis of Fc binding protein has been 
well documented for the analogous functions carried by VZV, pseudorabies virus (PrV) and HSV-1. 
The VZV gE protein undergoes clathrin-dependent endocytosis mediated by a tyrosine-based motif of 
its cytoplasmic tail [26]. Postendocytotic events include recycling to the plasma membrane or TGN 
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sorting mediated by an acidic cluster [31]. Internalization of VZV gE is enhanced upon association 
with the escort protein gI, a glycoprotein deprived of Fc binding activity but possessing independent 
internalization and trafficking motifs [27,28]. Correct targeting of gE:gI complex to TGN is crucial for 
the formation of the viral particle [29]. For PrV, gE is responsible for the ligand-independent 
internalization of gE:gI since gI alone is unable to undergo endocytosis [30]. The gE:gI complex 
expressed by HSV contains several internalization motifs on their cytoplasmic tails. Such as its VZV 
counterpart, the HSV gE C-terminal includes a tyrosin-containing motif crucial for TGN sorting of the 
gE:gI complex, an event that also drives correct targeting of viral particles [31–33]. However, gE:gI 
complex from HSV displays an Fc binding-independent crucial function in cell-to-cell spreading of 
the virus and requires primary TGN accumulation followed by redistribution to cell junction [34]. 
In this report we investigate the HCMV Fcγ binding proteins UL119 and RL11, demonstrating that 
both proteins are able to internalize human IgG. We characterized this ability in terms of internalization 
pathway and intracellular route of the ligand. We also define the localization of UL119 and RL11 in 
infected cells and on purified HCMV virions, demonstrating that both proteins associate with the viral 
envelope. Finally we started to define the IgG internalization ability in HCMV infected cells.  
Chapter 2 
36 
  
RESULTS AND DISCUSSION 
Expression, glycosylation and intracellular localization of TR UL119 and RL11  
Immunoglobulin internalization mediated by viral Fcγ receptors (vFcγR) has been reported for 
different herpesviruses. Endocytotic activity of Cytomegalovirus Fc binding proteins UL119 and RL11 
was proposed by Atalay et. al. [22], based on the observation that both proteins were targeted to 
degradation in endolysosomal compartments, but never experimentally addressed. Internalization upon 
cell surface IgG binding was supported also by the presence of endocytic motifs in the C-terminal tail 
of both proteins (YxxL and DXXXLL motifs for UL119 and RL11, respectively [22]). We decided to 
characterize expression, localization and IgG internalization ability of UL119 and RL11 starting from 
the analysis of the recombinant protein transiently expressed in cell cultures.  
The sequences for both genes were derived from clinical CMV strain TR and cloned as codon 
optimized genes in the mammalian expression vector pcDNA3.1-mycHis. The expressed proteins 
included C-terminal double tag that was used for the detection. Western blot analysis in transiently 
expressing HEK293T cells showed the presence of two species for both UL119 and RL11 proteins with 
a molecular mass of approximately 120 kDa and 98 kDa for the former and 48 kDa and 40 kDa for the 
latter (Fig. 1A, first lane left and right panels, respectively). TR UL119 is a 345 residue protein with a 
calculated MW of 38.72 kDa that possesses 12 consensus Asn for N-linked glycosylation plus 26 O-
linked carbohydrate acceptor Thr or Ser, thus  with a high potential to be post-translational modified by 
glycosylation. Furthermore, our products include additional 3 kDa due to the presence of the myc and 
His tags. Digestion with endoglycosidase H reduced the molecular mass of both UL119 species to 102 
kDa and 40 kDa, respectively (Fig. 1A, second lane, left panel). PNGase F treatment of UL119 further 
reduced the molecular mass of both species to about 55 and 38 kDa for the slower and faster migrating 
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band respectively (Fig. 1A, third lane, left panel). This pattern suggests that the slower migrating 
UL119 form includes O-linked glycosylation. Treatment with tunicamycin, an ER N-linked 
glycosylation inhibitor, of UL119 resulted in a band of 38 kDa, confirming the complete 
deglycosylation of the EndoH sensitive band (Fig. 1A, fourth lane, left panel). The RL11 protein 
carried by the TR strain is 234 residues long with a calculated molecular weight of about 26.7 kDa. On 
its sequence, 4 Asn and 2 Thr acceptors of N-and O-linked glycan respectively are predicted. 
Treatment with either EndoH, PNGase F or with tunicamycin lead to the appearance of a single band at 
32 kDa (Fig. 1A, second, third and fourth lanes, right panel) suggesting that this species is not subject 
to heavy Golgi modification and does not receive O-linked carbohydrates. Although the analysis shown 
has been performed in HEK293T cells, identical results were obtained with proteins expressed in 
epithelial ARPE-19 cells (data not shown).  
The analysis of glycosidase digestion suggested that, as single gene transfection, UL119 is present 
in two main post-translational modified species, the faster migrating likely localized at early steps of 
the secretory pathway while the slower migrating species represent a post-Golgi product. RL11 showed 
a simpler glycosylation pathway only as non-complex N-linked glycans.  
To assess the plasma membrane localization of UL119 and RL11, cytofluorimetric analysis on 
transiently transfected cells was performed. HEK293T cells expressing YFP-tagged proteins were 
stained 24 h post transfection with mouse sera against RL11 and UL119 (Fig. 1B, left and central 
panels, respectively). In both cases, a signal higher than control was registered confirming UL119 and 
RL11 surface localization in our system. Surface exposed proteins were also corrected folded as 
confirmed by their ability to bind fluorescent Fcγ in non-permeabilized cells (Fig. 1B, right panel). 
These experiments demonstrated that in our system both proteins are able to reach the plasma 
membrane and to assume a full functional conformation.  
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In figure 2 is shown the intracellular localization of RL11 and UL119 performed by confocal 
microscopy in ARPE-19 human epithelial cells. Similar results, however, were obtained with human 
derived fibroblastoid cell line MRC-5 (not shown). Transiently transfected cells, expressing YFP-
tagged UL119 and RL11, were fixed, permeabilized and stained with different markers of the secretory 
apparatus. At steady state, total intracellular pool of both UL119 and RL11 is revealed by the YFP 
(green in Fig. 2) and is mainly constituted from vesicles co-localizing with markers of the early 
endosomes such as EEA1 and Rab5 (Fig. 2, middle and lower panels). In these conditions, we did not 
find significant co-localization with lamp1, a marker of the lysosomal compartment (not shown). These 
results suggested that UL119 and RL11 undergo endocytosis from the plasma membrane to early 
endosomes in transfected cells, but questioned a targeting to degradation pathway. The human IgG Fc 
binding ability of UL119 and RL11 is displayed in the upper panel of Fig. 2. Most of the intracellular 
fraction of both proteins was able to bind human immunoglobulin as showed by the co-localization 
with a fluorophore conjugated human IgG Fc fragment (Fc, Fig. 2, upper panel). However, for both 
proteins a minor fraction did not bind the Fcγ, perhaps immature proteins entering the initial steps of 
the secretory pathway. 
Taken together, these data indicate the transport of these two Fcγ-binding proteins to plasma 
membrane followed by internalization and long lasting into vesicles with marker of early endosomes.  
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Fig. 1:  
A. Deglycosylation profiles of UL119 and RL11. Western blot of UL119 and RL11 proteins 
transiently expressed from HEK293T. Size of the native forms or after treatment with Endoglycosidase 
H, PNGaseF and Tunicamycin are shown. Endoglycosidase H sensitive and resistant isoforms are 
indicated (black and gray arrows, respectively).  
B. Membrane localization and Fcγ binding ability of UL119 and RL11 Cytofluorimetric analysis of 
HEK293T expressing RL11-YFP (green lines) and UL119-YFP (red lines). Cells were stained with 
either anti-RL11 or anti-UL119 mouse anti-sera (left and central panels, respectively) or with a 
fluorophore conjugated human IgG Fc fragment (right panel). Signals retrieved from YFP positive cells 
were compared to empty vector transfected control cells. Each histogram represents 1x10
4
 cells.   
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Fig. 2: UL119 and RL11 localized with markers of endocytic pathway. ARPE-19 grown on glass 
coverslips were transfected with vectors coding for C-terminus YFP fused UL119 and RL11 proteins 
(green color, left and right panels, respectively). Cells were fixed, permeabilized and stained with 
human IgG Fc fragment (Fc, red color on top) and with markers of the early endosomes (EEA1 and 
Rab5 middle and bottom panels, respectively) before being analyzed trough confocal microscopy. 
Merge panels show the superimposition between green and red colors. The boxed regions in the 
merged images are magnified.   
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Immunoglobulin Fc fragment internalization ability of recombinant UL119 and RL11  
Having defined the presence on the plasma membrane of UL119 and RL11 in transfected cells, we 
sought to investigate ability of these two proteins to internalize upon binding of the Fcγ fragment. 
ARPE-19 cells transiently expressing C-terminus YFP-tagged UL119 and RL11 were incubated on ice 
with fluorescently labelled Fcγ. Incubation was protracted for 30 min, then the excess of fluorescent 
probe was washed out while cells were either fixed (time 0) or incubated in complete medium for 30 
min at 37°C to allow for internalization. Cells were then fixed and submitted to confocal microscopy 
analysis (Fig. 3). As expected, cells that were not switched at 37°C showed a marked membrane 
staining due to the binding on the plasma membrane of the Fcγ fragment. This result was similar for 
both UL119 and RL11 transfected cells (Fig. 3 upper rows, left and right panels, respectively). Re-
establishment of membrane trafficking after temperature switching allowed endocytosis of the human 
Fcγ from the plasma membrane and both proteins and Fcγ completely co-localized into intracellular 
vesicles (Fig. 3, bottom panels). Kinetic of the internalization process was followed over the time 
through live microscopy on UL119-YFP expressing cells (Fig. 4). Small vesicles containing Fcγ signal 
can be seen as short as 4 min after immunoglobulin G fragment addition to the culture medium (Fig. 4, 
white arrow upper right panels). Fcγ accumulated inside endosomes, whose dimension increased, in 
spite of a decrease in number, during the time course (white arrows in left zoomed panels and data not 
shown). Furthermore, the overnight live imaging revealed only a slight decrease of Fcγ signal bound to 
the fluorescent UL119, suggesting that the endosomes were not targeted to lysosomes (data not shown). 
These observations assessed that both recombinant UL119 and RL11 were able to internalize human 
IgG Fc fragment from the plasma membrane and are consistent with the lack of lysosomal delivery of 
the cargo.   
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Fig. 3: UL119 and RL11 internalized human IgG Fc fragment in transfected cells. ARPE-19 cells 
grown on glass coverslips were transfected with plasmids expressing C-terminally YFP fused UL119 
and RL11 proteins (green color, left and right panels, respectively). 48 h post transfection, 649 Dylight 
conjugated human IgG Fc fragment (Fc, red color) was added for 30 min on ice. Cells were washed and 
either fixed (t0) or shifted at 37°C for 30 min prior fixation (t30) to allow for internalization.  
 
 
 
 
 
 
 
 
 
Fig. 4: UL119 Fcγ live-microscopy internalization assay. UL119-YFP (green color) expressing 
ARPE-19 were imaged live during Fcγ (red color) uptake from culture medium. One frame per minute 
was taken. Scale bar 10 μm. Images enclosed in white boxes are showed in the zoomed panels. Co-
localization between UL119 and Fcγ signals is shown in yellow.  
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Internalization of Fcγ by UL119 and RL11 is clathrin dependent 
Receptor mediated endocytosis of small IC and soluble IgG by cFcγ is dependent on both clathrin 
and dynamin [35,36]. Clathrin dependent endocytosis relies on the interaction with a small set of 
adaptor proteins and a huge number of accessory proteins, which regulate different aspects of the 
endocytosis [37]. Overexpression of the C-terminus, containing the clathrin binding domain, of adaptor 
protein AP180 (AP180-C), leads to the redistribution of clathrin and the complete inhibition of clathrin 
mediated endocytosis [38]. To define whether the internalization pathway of the two CMV Fcγ binding 
proteins UL119 and RL11, follows the above mentioned mechanism, a vector expressing the AP180-C 
was used. Internalization of Fcγ was assayed on ARPE-19 cells transiently co-expressing UL119 or 
RL11 with AP180-C. Results of the assay are showed in figure 5. When clathrin endocytosis was 
abrogated, Fcγ was observed only at the plasma membrane of UL119 and RL11 positive cells (Fig. 5, 
top panel of A and B, respectively). On the contrary, distinct punctate signals were present at the same 
time in control cells expressing the CMV proteins alone (Fig. 5A-B, bottom panel). Same pattern was 
observed for transferrin, whose transport depends on clathrin internalization (Fig. 5C), confirming the 
inhibitory activity of AP180-C protein in our system. These experiments showed that Fcγ fragment 
internalization pathway by UL119 and RL11 relied on clathrin-coated pits formation.  
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Fig. 5: Overexpression of dominant-negative mutant of AP180 inhibited UL119 Fcγ endocytosis. 
ARPE-19 were transiently transfected with UL119-YFP or RL11-YFP alone (lower panels of A and B, 
respectively) or in combination with myc-tagged AP180 (A and B, top panels). At 48 h post 
transfection, cells were allowed to internalize 549 Dylight conjugated human IgG Fc fragment for 30 
min at 37 °C (A-B, red color). For transferrin uptake (C), cells were serum starved for 1 h at 37 °C, and 
then incubated with 50 μg/ml 568 Alexa fluor conjugated transferrin (Tfn, red color) in DMEM without 
serum at 37 °C for 30 min. At the end of endocytosis, cells were cooled to 4°C quickly, washed and 
fixed. Endocytosis was analyzed by confocal laser-scanning microscope.  
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UL119 and RL11 localize in the viral assembly complex and associate with the virion envelope. 
The IgG Fcγ internalization ability and endocytic trafficking of UL119 and RL11 suggested their 
potential involvement in antiviral IgG removal from the surface of infected cells. However, lack of co-
localization with endolysosomal markers argue against a possible lysosomotropic function. This could 
be explained considering the system under analysis that is the transient transfection of single proteins. 
Additional protein functions could be needed to alter the intracellular transport. The strong remodeling 
of the secretory apparatus in CMV infected cells and the huge number of viral proteins expressed 
during the course of the infection could affect and modify the observed vFcγ endocytosis mechanism 
[39–41]. To this aim, we decided to analyze the UL119 and RL11 Fcγ internalization ability in the 
context of the CMV infection. First we defined the intracellular distribution of both proteins in CMV 
infected human foreskin fibroblast (HFF). TB40E strain, harboring GFP sequence in frame with the 
gene coding for the viral tegument protein pp150 [42], was used for the first experiment (Fig. 6, upper 
panel). Cells seeded on glass coverslips were infected for 5 days before being fixed, permeabilized and 
stained using specific anti-sera developed in mouse against UL119 and RL11. As reported in literature 
[43], accumulation of pp150 in a large cytoplasmic perinuclear inclusion, compatible with the viral 
assembly complex (AC), was observed. Signals retrieved from UL119 and RL11 anti-sera concentrated 
to the same intracellular structure, co-localizing with pp150 tegument protein (Fig. 6, upper green and 
merge panels, respectively). To further confirm the presence of UL119 and RL11 in the assembly 
complex, staining of glycoprotein gL (a virion envelope glycoprotein encoded by gene UL115) and 
trans-Golgi network (TGN46 marker) was performed on cells infected with CMV TR strains coding for 
tagged version of both viral Fcγ proteins. The Flag and HA epitopes were used to track UL119 and 
RL11 expression, respectively. Both proteins co-localized with gL glycoprotein and partially with the 
trans-Golgi marker. The latter also surrounded the sites of UL119 and RL11 accumulation, consistent 
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with the reported reorientation of trans-Golgi compartment at the outer edge of the assembly complex 
[44]. 
The observation that UL119 and RL11 localized at the virion assembly site suggested their 
potential inclusion in the virion envelope as surface exposed glycoproteins. To test this hypothesis 
virions were purified from infected HFF and subjected to detergent fractionation in order to separate 
envelope embedded proteins from tegument and capsids ones. Results from these studies are shown in 
figure 7. Both UL119 and RL11 co-purified with envelope glycoprotein B (gB) in the envelope fraction 
(E). No co-elution of UL119 and RL11 in the tegument/capsid fraction, defined by the presence of 
tegument protein pp65, was observed (Tc lane). The UL119 presence on purified virus was already 
reported in literature by Varnum and co-authors [25]. Through a mass spectrometry analysis of purified 
virions they were able to detect peptides derived from proteolitic digestion of UL119. However the 
approach could not provide any information regarding the localization of the protein. Our analysis 
revealed and defined the presence of both Fcγ binding proteins as envelope associated proteins. 
Recently, our group identified two novel Fcγ binding proteins, RL12 and RL13 [21]. The latter has 
been reported as envelope associated protein by Stanton and co-workers [24]. The fact that almost all 
the HCMV Fcγ binding proteins identified so far are exposed on the envelope can imply an important 
role for these functions. For example, the antibody bipolar bridging mechanism, described for HSV Fcγ 
binding proteins gE-gI [45], can be activated on the HCMV surface by exposed proteins with Fcγ 
binding ability, allowing the virus to escape immune system recognition.   
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Fig. 6: UL119 and RL11 localized within the viral assembly complex in HCMV infected cells. 
HFF cells were infected with TB40E-pp150-EGFP (upper panels), TR-UL119Flag and TR-RL11HA 
(middle and bottom panels, top and bottom rows, respectively). 5 d.p.i. cells were fixed, permeabilized 
and stained. UL119 and RL11 (green color) were detected either with mouse anti-sera or with anti-tag 
antibodies. Tegument protein pp150, envelope glycoprotein gL and trans-Golgi network protein 
TGN46 were either expressed in fusion with GFP or stained with antibodies (red color). Z-stacks were 
collected with a confocal microscope. Representative Z-stack projections of each sample are shown.  
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Fig. 7: UL119 and RL11 are CMV envelope glycoproteins. Analysis of UL119 and RL11 in TB40E-
pp150-GFP virions purified from 5 days infected HFF cells. Complete virions (V), tegument/capsid 
fraction (Tc) and envelope fraction (E) were probed for the antigens indicated.  
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Internalized human IgGs do not undergo lysosomal degradation in infected cells  
Uptake of both human IgG and Fcγ fragment in infected cells was first reported in 1976 by Keller 
and co-authors [46]. However the fate of human IgG upon internalization has not been defined yet. We 
decided to investigate the route of Fcγ internalization and the role of viral Fcγ binding proteins in the 
contest of productive infection. For these studies, wild type TR and a mutated TR strain encoding for 
YFP version of UL119 were used. HFF infected for 5 days with CMV TR strains were incubated with 
labeled Fcγ fragments for 60 min on ice. Cells were then washed and temperature was raised to 37°C to 
allow for internalization. At different times after temperature switching, cells were fixed and stained for 
markers of the endocytic machinery. A strong colocalization between Fcγ fragment and the vFcγ 
binding proteins (Fig. 8, green and magenta colors, respectively) was found throughout all time points. 
At 30 min, Fcγ was present in early endosomes and was retained within early endosomes up to the 
latest time of observation (Fig. 8, first and second rows, fourth and sixth panels). Moreover, Fcγ 
positive vesicles did not fuse with lysosomes as suggested by lack of co-localization with lysosomal 
marker Lamp1 after 120 min from the internalization start (Fig. 8, third row, red color in fourth and 
sixth panels). 
While no direct evidences are yet available, the lack of co-localization with lysosomal markers, the 
retention in EEA1 positive vesicles and the accumulation in the viral assembly complex site allow us to 
speculate for a possible insertion of human Fcγ fragment in the budding virions. Indeed the insertion of 
human immunoglobulins in the HCMV virion upon budding from infected cells has been reported [47]. 
Manley and co-authors [47] demonstrated that HCMV virus produced in presence of sub-neutralizing 
doses of anti gH human monoclonal antibody MSL-109 gain antibody resistance through IgG 
internalization and virion cloaking. Nevertheless in the same paper, two observations argue against our 
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model. First the phenomenon seems to be specific for the MSL-109, because no insertion of IgGs in the 
virion was observed when the human anti-gB neutralizing antibody ITC88 was tested. Second, resistant 
virus genetically abrogates the UL119 and the RL13 functions. Thus, the fate of internalized human 
IgG by infected cells still need to be fully addressed. This understanding could be crucial in order to 
gain better insight into potential mechanism used by the virus to escape immune system response and 
allow a better design of antiviral therapies.  
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Fig. 8: Endocytosed human Fc fragment is retained in the early endosomes. HFF were infected 
with TR-UL119YFP. 5 d.p.i. cells were incubated with 647 Dylight conjugated human IgG Fc 
fragment on ice for 60 min before being washed and shifted to 37°C to allow for internalization. At the 
indicated time points, cells were fixed and stained with antibodies against early endosomes and/or 
lysosomes (red color, EEA1 and Lamp1, respectively). Images were collected through confocal 
microscopy. Z-stack projections of representative pictures are shown. Superimposition of signals from 
human Fc (Fc, green color), cellular markers and with or without UL119YFP (magenta color), are 
shown in the merge panels (fifth and sixth columns, respectively).  
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MATERIALS AND METHODS 
Cells, plasmids and antibodies 
ARPE-19, MRC-5, HFF and HEK293T cell lines were purchased from ATCC (catalogue numbers 
CRL-2302, CCL-171, CRL-2429 and CRL-11268, respectively) and cultured according to the 
supplier’s instructions. DMEM high glucose and DMEM:F12 media (Gibco, Invitrogen) were 
supplemented with 10% fetal calf serum (FCS) and penicillin streptomycin glutamine (Gibco, 
Invitrogen). Lipofectamine 2000 (Invitrogen) was used to transfect HEK293T cells, while Fugene 6 
(Roche) and Nucleofector kit V (Amaxa) were used to transfect ARPE-19 cells as suggested by 
manufacturer. Human codon-optimized UL119 and RL11 genes, from HCMV TR strain, were 
synthesized by Geneart and cloned in plasmid pcDNA3.1(-)/myc-His C (Invitrogen) in frame with C-
terminal myc and six histidine tag sequences. Fluorescent fusion proteins were obtained by subcloning 
the genes of interest upstream of the EYFP sequence in pEYFP-N1 vector (Clontech). Primary 
antibodies used in this work were: anti-His_C-term (Invitrogen), anti-PDI (Invitrogen), anti-HA 
(Invitrogen), anti-Rab5 (Santa Cruz), anti-Rab11 (Santa Cruz), anti-Rab7 (Santa Cruz), anti-lamp1 
(Santa Cruz), anti-GM130 (Abcam), anti-TGN46 (AbD Serotec), anti-EEA1 (Abcam). All primary 
antibodies were produced in mouse. Mouse anti-sera recognizing UL119 and RL11 were developed in 
house. Briefly, His-tagged peptides encompassing the amino acid regions 107-254 of UL119 and 111-
180 of RL11 from TR strain were produced in E. coli and purified through metal ion affinity 
chromatography. Purified peptides were used to immunize mice. Secondary antibodies used in this 
study were: Alexa Fluor F(ab)2 fragment of 488-, 568-, and 647-conjugated goat anti-mouse (Invitrogen) 
and HRP-conjugated secondary antibodies from Perkin Elmer. Chrompure DyLight 649-, 549- 
conjugated human Fc fragments were purchased from Jackson Immunoresearch.  
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Glycosidase and tunicamycin treatments 
For deglycosylation treatments, 20 µg of protein extract was incubated either with 2.5 µl of 
Endoglycosidase H (Endo Hf, NEB) or 2.5 µl peptide-N-glycosidase F (PNGaseF, NEB) or buffer only 
for 3 h at 37°C according to the manufacturer’s protocol. Samples were analyzed by Western 
immunoblotting. 
For tunicamycin treatments, HEK293T cells were incubated for 24 h with 2 µg/ml of tunicamycin 
A (Sigma) and then subjected to lysis with RIPA lysis buffer (SIGMA) supplemented with protease 
inhibitors (Roche). 
 
Flow cytometry  
To define the proteins plasma membrane localization, HEK293T cells transiently expressing 
UL119, RL11 and empty vector were harvested with trypsin 48 h post transfection and subjected to 
staining with mouse anti-serum. Briefly, cells were incubated 30 min at RT with Live&Dead Agua 
(Invitrogen) diluted 1:400 in PBS, washed twice and incubated with for 30 min with blocking buffer 
(PBS with 5% FBS). Mouse anti-sera, diluted 1:100 in blocking buffer, were added for 60 min on ice. 
Cells were washed 3 times in PBS and then incubated with Alexa Fluor F(ab)2 fluorophore conjugate 
secondary antibodies for 30 min on ice. Cells were washed thrice in PBS before being analyzed. When 
intracellular staining was required, cells were permeabilized with Cytofix/Cytoperm kit (BD) and 
perm/wash buffer was used in all subsequently steps. For cells expressing the myc tagged proteins, 
anti-myc-FITC antibody (Invitrogen) was used at 1:500 dilution. Binding of the Fc portion of the 
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human IgGs (Fcγ) was assessed using Dylight 649 conjugated human IgG Fc fragment (Jackson 
Immunoresearch) at different dilutions (50 µg/ml, 10 µg/ml and 5 µg/ml).  
A total of 10
4
 cells were analyzed for each histogram using a FACSCanto II (Becton Dickinson). 
 
Confocal microscopy analysis 
Cells expressing the proteins of interest were grown on glass coverslips or glass chamberslides. For 
intracellular staining, cells were fixed 48 h post transfection with 3.7% paraformaldehyde and 
permeabilized with 0.1 % Triton X-100 (Sigma). For membrane staining, the permeabilization step was 
omitted and fixation was performed after staining with primary and secondary antibodies for 60 min on 
ice. In both cases, cells were incubated in blocking buffer (PBS + 5% FBS) for 30 min before antibody 
staining. Antibodies were always diluted in blocking buffer.  
For human Fcγ internalization, cells transiently expressing YFP- tagged UL119, RL11 or YFP only 
(control) were plated on glass coverslips 24 h post transfection. 24 h later, cells were washed in cold 
PBS and incubated at 4°C with 20 μg/ml of DyLight 649-conjugated human Fcγ for 60 min. After 
extensive washes, temperature was switched to 37°C to allow for internalization. When required, cells 
were fixed, permeabilized and stained before mounting.  
For intracellular localization and internalization analyses in infected cells, HFF were seeded on 
glass coverslips and infected for 5 days with HCMV. Staining and internalization protocols were then 
performed as described above. When applicable, 5% non-immune human serum was added to blocking 
buffer in order to reduce non-specific signal. 
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The intracellular locations of antibody-tagged or fluorescent fusion proteins were examined under 
laser illumination in a Zeiss LMS 710 confocal microscope and images were captured using ZEN 
software (Carl Zeiss). Live microscopy experiments were performed with a Zeiss Axio Observer 
widefield fluorescence microscope. 
 
HCMV virions purification and virion proteins fractionation 
Mature HCMV virions were separated from dense bodies (DB) and noninfectious enveloped 
particles (NIEPs) through a positive density/negative viscosity step-gradient centrifugation as described 
previously (Talbot et al). Briefly, medium from infected cells was collected when 100% cytopathic 
effect was observed and subjected to 3500 rpm centrifugation for 20 min at 16°C. Supernatant was 
transferred to polycarbonate tubes underlied with 20% sucrose and centrifuged for 60 min at 23000 
rpm in a Beckman SW32Ti rotor. Pelleted virus was resuspended in 1 ml PBS and 2 ml of 4 different 
solutions containing decreasing concentration of sucrose and increasing concentration of glycerol 
tartarate were layered underneath. Tubes were centrifuged at 42000 rpm for 60 min at 10°C in a 
Beckman SW28Ti rotor. Band containing mature virions was collected through a syringe, resuspended 
in PBS, centrifuged for 60 min at 23000 rpm in a Beckman SW32Ti rotor and the pellet containing 
virus was resuspended in PBS. Quality of the purification was assessed through negative staining 
electron microscopy (EM) analysis. To separate envelope from capsid and tegument proteins, purified 
virions were mixed 1:1 with envelope extraction buffer (1% NP-40 and 4% Sodium Deoxycholate) and 
incubated on ice for 30 min with occasional vortexing. Soluble fraction was collected through max 
speed centrifugation in a benchtop centrifuge for 30 min at 4°C. The insoluble pellet was washed twice 
in PBS before being solubilized in SDS-PAGE sample buffer. For each extraction, a total of 4 
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confluent T175 cm
2
 flasks of HFF cells were infected. Virus was purified as described above and 10% 
was mixed with SDS-PAGE loading buffer while the rest was subjected to proteins extraction.   
 
Construction and generation of TR-RL11HA, TR-UL119Flag, TR-RL11HA/UL119Flag and 
TR-UL119YFP 
Markerless two-step RED-GAM BAC mutagenesis was used to generate recombinant viruses 
harboring tagged version of RL11 and UL119 genes in their genome [48]. Briefly, kanamycin 
resistance cassette, flanked by I-SceI restriction enzyme cleavage site, was PCR amplified from pEP-
KanS shuttle vector. The primers used contained homologous regions to allow the integration of the 
amplicon in the region of interest of the BAC DNA through lambda Red recombinases induction. 
Combination of I-SceI cleavage with a second Red recombination event removed the resistance gene 
leaving only the new sequences of interest. The primers used to generate the mutated HCMV strains 
were (Table 1, supplemental material): for TR-RL11HA, RL11HAFw and RL11HARv on pEP-KanS 
plasmid as template; for TR-UL119Flag, UL119FlagFw and UL119FlagRv on pEP-KanS plasmid as 
template; for TR-UL119YFP, UL119YFPFw and UL119YFPRv on pEYFP-KanS plasmid as template. 
Recombination events were performed with E. coli GS1783 strain containing a BAC clone of the 
HCMV TR strain. The E. coli strain contains also the lambda Red system and the I-SceI genes under 
the control of heat shock- inducible and arabinose-inducible promoters, respectively. The desired 
mutations were confirmed by sequencing and integrity of the whole recombinant HCMV genomes was 
checked through restriction analysis.  
To construct the pEYFP-KanS shuttle vector, a BclI restriction enzyme site was inserted in the 
pEYFP-N1 plasmid by Quickchange site directed mutagenesis (Stratagene) as suggested by the 
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manufacturer with primers YFPmutBclIFw and Rv (Table 1, supplemental material). Methylation of 
the restriction site was abrogated inserting the mutated pEYFP-N1 plasmid in the Inv110 E. coli strain. 
Unmethylated plasmid DNA was collected and linearized with BclI. A kanamycin gene with an 
adjoining I-SceI site and a region homologue to the YFP gene was amplified from the pEP-KanS 
plasmid with primers YFPKanS Fw and Rv (Table 1). pEYFP-KanS shuttle vector was obtained 
inserting the antibiotic cassette in the linearized plasmid.  
To reconstitute the virus, MRC-5 cells from a confluent T175 cm
2
 were trypsin detached, mixed 
with 10 µl fresh prepared BAC DNA (around 3 µg) and 1 µg of pCMVKm2-pp71 plasmid and 
electroporated in 4 mm cuvette at 250 V and 950 µF. Supernatant containing virus was collected from 
infected cells when cytopathic effects were >90%. For all following infection experiments, human 
foreskin fibroblast (HFF) cells were used. 
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Table 1: Oligonucleotides used in this study. 
Name Sequence 
RL11HA Fw  GGATACGGAACCTTTGTTGTTGACGGTGGACGGAGATTTGGAATACCCTTACGACGTGCCTGACTACGCCAGGATGACGACGATAAGTAGGG 
RL11HA Rv  
TGTCGGTACGTAAGGTTGTTGCGTCTTTGACGGTTGACGCGCATCTTTTAGGCGTAGTCAGGCACGTCGTAAGGGTATTCCAAATCTCCGTCCA
CCGTCACAACCAATTAACCAATTCTGATTAG 
YFPKanS Fw ATATGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGGATAAGTAGGGATAACAGGGT 
YFPKanS Rv ATATGATCACAACCAATTAACCAATTCTGATTAG 
UL119YFP Fw AGGAGCCCGTTGAGGAAAAGAAACACCCGGTGCCCTACTTCAAGCAGTGGCGGGATCCACCGGTCGCCACC 
UL119YFP Rv AAGTCAGCGAAATAAAGACAACACAGCAGCCACTCCTCTCGTCTCGGGCCTTACTTGTACAGCTCGTCCATG 
YFPmutBclI Fw CAACGAGAAGCGTGATCACATGGTC 
YFPmutBclI Rv GACCATGTGATCACGCTTCTCGTTG 
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ABSTRACT 
The human cytomegalovirus (HCMV) protein RL13 has recently been described to be present in all 
primary isolates but rapidly mutated in culture adapted viruses. Although these data suggest a crucial 
role for this gene product in HCMV primary infection, no function has so far been assigned to this 
protein. Working with RL13 expressed in isolation in transfected human epithelial cells, we 
demonstrated that recombinant RL13 from the clinical HCMV isolates TR and Merlin have selective 
human immunoglobulin (Ig)-binding properties towards IgG1 and IgG2 subtypes. An additional Fc 
binding protein, RL12, was also identified as an IgG1 and IgG2 binding protein but not further 
characterized. The glycoprotein RL13 trafficked to the plasma membrane where it bound and 
internalized exogenous IgG or its constant fragment (Fcγ). Analysis of RL13 ectodomain mutants 
suggested that the RL13 Ig-like domain is responsible for the Fc binding activity. Ligand-dependent 
internalization relied on a YxxL endocytic motif located in the C-terminal tail of RL13. Additionally, 
we showed that the tyrosine residue could be replaced by phenylalanine but not by alanine, indicating 
that the internalization signal was independent from phosphorylation events. In sum, RL13 binds 
human IgG and may contribute to HCMV immune evasion in the infected host, but this function does 
not readily explain the instability of the RL13 gene during viral propagation in cultured cells.  
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INTRODUCTION 
Human cytomegalovirus (HCMV) infection is common and, although typically subclinical in the 
healthy population, it can cause severe disease in congenitally infected infants and in individuals with 
suppressed immunity [1]. In immunocompetent individuals, infection is controlled by both cellular and 
humoral immune responses, defenses that are weakened in immunocompromised patients leading to 
infection of several tissues and a vast range of cell types [2]. 
Characterization and use of clinical and low passage isolates of cultured HCMV strains have led to 
a reconsideration of the viral coding potential and suggested the presence of new unidentified functions 
(reviewed in [3]). Comparative sequencing analysis of unpassaged clinical isolates versus cell culture 
adapted viruses allowed a more refined identification of the genetic changes corresponding to functions 
that are lost in in vitro cultures. This is the case of RL13 and UL128 gene products, both possessing a 
suppressive phenotype on tissue culture adapted viruses [4,5]. For RL13 in particular, Stanton et al. 
recently reported rapidly emerging genetic mutations following a few passages of BAC-derived Merlin 
strain virus in cultures of human cells of different origins [6]. These authors, using an elegant BAC 
system of conditional gene repression during virus propagation, were able to show that virus with 
reconstructed wild type RL13 repressed cell culture growth while the emerging deletion mutants 
allowed the virus to adapt to cell culture growth [6]. Providing that a functional RL13 gene appears to 
be carried by all sequenced clinical isolates, the authors hypothesized that this protein is critical for 
productive HCMV replication in vivo, perhaps increasing the repertoire of HCMV cell tropism [6].  
HCMV has evolved a number of different ways to evade the immune system, often employing 
seemingly redundant factors and mechanisms to maintain the lifelong infection of the host [7]. 
Limitation of the host antibodies and complement activities through the expression of viral proteins 
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able to bind the constant region of immunoglobulin G (Fcγ) is a mechanism common to several 
herpesviruses [8,9]. These viral proteins interfere with the host receptors for the Fc portion (FcγRs) of 
immunoglobulin G (IgG), expressed on the surface of all cell types in the innate and adaptive parts of 
the immune system [10]. 
FcγRs are a complex family of proteins with several distinct classes and subclasses that function at 
the interface of the adaptive and innate immune systems [10]. They sense immune complexes in the 
extracellular environment and regulate signaling cascades in effector cells, which may contribute 
significantly to balancing pro- and anti-inflammatory responses to infection. HCMV expresses two 
proteins of 34 and 68 kDa that bind the Fc region of IgGs [11–13]. gp34 is encoded in clinical isolates 
by RL11 and in laboratory isolates by the duplicate genes TRL11 and IRL11 [12,14]. gp68 is translated 
from the spliced mRNA encoded by UL119 and UL118 [11] and has been detected in preparations of 
purified virions [15]. Both gp34 and gp68 are glycosylated type I membrane proteins predicted to form 
immunoglobulin supergene family (IgSF)-like domains [11]. They bind all classes of human IgG with 
approximately equal affinity, whereas gp34 also binds rabbit IgG and, to a lesser extent, rat IgG1. 
In this report we identified two additional Fcγ binding activities encoded by the HCMV genome, 
RL12 and RL13, and characterized this property of recombinant RL13 from the TR and Merlin strains 
of HCMV. We demonstrated that RL13 transfected into cultured human epithelial and fibroblast cells 
binds and internalizes the Fc portion of human IgGs.   
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RESULTS 
Fcγ binding ability of selected members of the RL11 family 
RL11 was the first identified Fcγ binding protein of HCMV [12] and is hypothesized to function 
through its Ig-like domain [11]. Using RL11 as positive control, we sought to test if RL10, RL12 and 
RL13 were also able to bind human IgGs. We included gB (UL55) as a negative control. HEK293T 
cells were transfected with expression plasmids for myc-His tagged gB, RL10, RL11, RL12, RL13. 48 
h after transfection, flow cytometry analysis was performed with DyLight 649-conjugated human Fcγ 
and FITC-conjugated anti-myc. Permeabilized (Fig. 1A) and non-permeabilized (Fig. 1B) FITC-
positive cells were tested for ability to bind human Fcγ. RL11, RL12 and RL13 bind the Fc portion of 
human IgG while RL10 and gB are comparable to negative control (Fig. 1A and 1B). It appears that a 
large fraction of the Fcγ-binding activity of RL13 (brown trace) is surface exposed, whereas a large 
fraction of RL11 and RL12 (blue and green trace, respectively) is not (Fig. 1A and 1B). Expression of 
the different proteins was equal as demonstrated by comparable percentage of FITC positive 
populations and their mean fluorescence intensity (data not shown). Taken together, these data 
suggested that RL12 and RL13 are two previously unidentified human Fcγ binding proteins encoded by 
HCMV.  
RL11 has been shown to bind all different subclasses of human IgGs [11]. To assess if RL12 and 
RL13 differentially recognized human IgG subclasses, flow cytometry on permeabilized HEK293T 
cells expressing RL11, RL12, or RL13 was performed using individual human IgG subclasses as 
probes. Cells expressing RL11 bind all IgG subclasses whereas cells expressing RL13 appear to 
specifically bind IgG1 and IgG2 (Fig. 1C).  
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These data and similar analysis of RL12 binding to human Ig isotypes and binding of RL12 and 
RL13 to Igs from different species are summarized in Table 1. Although the finding that RL12 binds 
Fcγ was novel, we focused the rest of this report on RL13.  
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Figure 1: FACS analysis of Fcγ and IgG binding. 
A: Binding of Fcγ to RL13 in permeabilized cells. HEK293T cells transfected with empty vector or 
expression vectors for myc-tagged gB, RL10, RL11, RL12 or RL13 were fixed, permeabilized and 
stained using FITC-conjugated anti-myc and 25 µg/ml DyLight 649-conjugated human IgG Fc 
fragment (Fcγ). FITC positive cells were compared to mock transfected cells for their ability to bind 
Fcγ.  
B: Binding of Fcγ to surface-exposed RL13. HEK293T cells transfected with empty vector or 
expression vectors for myc-tagged gB, RL10, RL11, RL12 or RL13 were first stained at 4°C with 
DyLight 649-conjugated human IgG Fc fragment (25 µg/ml). Excess of probe was removed by 
washing in PBS and then cells were fixed and stained with FITC-conjugated anti-myc. FITC positive 
cells were compared to mock transfected cells for their ability to bind Fcγ.  
C: Binding specificity of RL10-RL13 towards different human immunoglobulin subclasses. HEK293T 
cells were transiently transfected with myc-tagged RL11 (blue), RL12 (green), RL13 (brown) or with 
empty vector (magenta). Cells were fixed, permeabilized and stained with FITC-conjugated anti-myc 
together with 10 µg/ml of human Ig of the different subclasses. Alexa fluor 647-conjugated goat anti-
human was used as secondary antibody. FITC positive cells were compared to mock transfected cells 
for their ability to bind Fcγ. 
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Table 1: Ig-binding specificity of Fc-binding proteins RL11, RL12 and RL13. 
HEK293T cells were transfected with expression plasmids encoding a tagged version of RL11 RL12, 
and RL13 genes, stained with the indicated immunoglobulins, and analyzed by flow cytometry. 
+/++/+++ indicates efficiency of Fc-binding observed as mean fluorescent intensity; − indicates no 
binding. 
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Amino acid residues 109 to 218 of TR strain RL13 are necessary for Fc binding 
The RL13 protein possesses strong topology similarities with the previously characterized HCMV 
Fc binding proteins coded by the RL11 and UL119 genes (gp34 and gp68 respectively) [11]. HCMV 
RL13 is a member of the RL11 multigene family [16] encoding a characteristic domain, known as 
RL11D or CR1 [17]. RL13 from HCMV strain TR has the typical features of a type I membrane 
glycoprotein (Fig. 2A): a 20 amino acids (aa) long signal peptide, a transmembrane domain in the 248-
268 aa region, and a predicted cytoplasmic tail of 26 aa in accordance with previous studies [6]. Further 
analysis suggests the likely presence of 11 N-linked glycosylation sites (pos. 21, 32, 37, 41, 90, 108, 
120, 167, 201, 208, 215 aa) and 22 O-linked glycosylation sites along the sequence, all restricted to the 
N-terminal region between residues 40 and 89. gp34 and gp68 contain a DxxxLL dileucine consensus 
motif for internalization and a potential I/V/L/SxYxxL intracytoplasmic immunoreceptor tyrosine 
based-like inhibition motif, respectively [11,12]. Similarly, we noted the presence of a tyrosine-based 
motif (YxxL) for intracellular targeting of transmembrane proteins [18] in the C-terminal cytoplasmic 
domain of the RL13 sequence (Fig. 2A). A search for conserved patterns in the TR RL13 ectodomain 
revealed an immunoglobulin (Ig)-like domain (Fig. 2A) identified as SM00409 (IG) in the SMART 
family classification (106-205 aa, with an HMMSmart E-value of 6.16e-04) [19]. A multiple sequence 
alignment generated from 15 different HCMV strains reported a very high conservation along the entire 
domain except 3 short regions predicted to form loops (Fig. 2B). All 15 sequence variants contain an 
immunoglobulin domain identified as SMART SM00409 or Interpro IPR013783 (E-values ranging 
from 9.9e-07 to 3.4e-04 and from 4.70E-07 to 6.10E-04, respectively). The secondary structure 
predictions suggested a propensity of the identified TR RL13 Ig-like domain to form a series of 8 beta-
strands (Fig. 2B).  
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To investigate the involvement of the Ig-like domain in the Fc binding ability, we produced 4 
different mutants of the RL13 ectodomain (Fig. 2C): RL13ΔNT, lacking 76 residues (aa 24-99) from 
the N-terminal region predicted to contain the O-linked glycosylation sites; RL13ΔE1, lacking 29 (aa 
218-246) residues between the Ig-like domain and the transmembrane region; RL13ΔE2 (aa 159-246), 
with the same deletion as above plus 57 residues of the C-terminus of the Ig-like domain; and RL13ΔIg, 
lacking the entire Ig-like domain (aa 109-218). The mutant proteins were transiently expressed fused to 
myc and His tags in HEK293T cells with comparable expression levels as judged by flow cytometry 
analysis using anti-myc antibody (data not shown). 
Fc binding ability was assayed by flow cytometry of myc-expressing permeabilized cells after staining 
with different concentrations of DyLight 649-conjugated Fc (Fig. 3A, only 12.5 μg/ml concentration is 
shown). Quantification of the results is reported as percentage of Fc stained cells in each sample 
compared to wild type RL13 (Fig. 3B). Values from RL13ΔNT were comparable to the wild type RL13, 
while a substantial reduction was observed in the RL13ΔE1 and RL13ΔE2 samples. Deletion of the Ig-
like domain carried by the RL13ΔIg (RL13ΔE1 and RL13ΔE2) mutants completely abolished specific 
Fc binding since the number of positive cells was comparable to negative controls, cells expressing 
RL10 or transfected with empty vector (Fig. 3A-B).  
These data indicated that the Fc binding activity of RL13 maps to amino acids 109-218. Removal 
of the region located between the Ig-like domain and the transmembrane domain severely impaired Fc 
binding but did not completely abrogate it. This observation suggests that this region could be 
important for the stability of the binding and/or the correct protein fold. 
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Figure 2: Predicted structure of the RL13 protein and schematic representation of TR RL13 
ectodomain mutants.  
A: Schematic representation of the HCMV TR RL13 full length protein. The signal peptide at the N-
terminus (SP), the Ig-like domain, the transmembrane domain (Tm), the tyrosine-based motif YxxL 
(Ym) sorting signal, 11 potential N-linked glycosylation sites (diamonds), and the O-linked 
glycosylation region (closed circles) are indicated. 
B: Multiple sequence alignment of the predicted RL13 Ig-like domain from the indicated strains of 
HCMV. The residues are colored according to the conservation level (red for higher conservation). 
Asterisks (*) below the alignments represent conserved amino acid in all sequences; colons (:) 
represent residues with similar physicochemical properties; dots (.) semi-conserved residues. The black 
arrows represent the positions of predicted β strands along the sequence.  
C: Graphic representation of TR RL13 and the ectodomain mutants used in this study. The amino-
terminal signal peptide, the carboxy-terminal transmembrane (gray boxes) and the Ig-like domain 
(white box) are indicated. 
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Figure 3: Fcγ-binding by RL13 ectodomain mutants.  
A: Cytofluorometric analysis of Fcγ binding by RL13 ectodomain mutants. HEK293T cells 
transfected with the indicated constructs were permeabilized and stained with DyLight 649-conjugated 
human IgG Fc fragment (Fcγ, 12.5 μg/ml) and Alexa Fluor 488-conjugated mouse anti-myc. Signals 
from 10,000 myc-positive cells are shown in each graph. The percentage of cells in each quadrant is 
indicated.  
B: Quantitative analysis of the FACS data. Each histogram shows the percentage of Fcγ positive 
cells relative to the RL13 wild type positive population (RL13). Values and error bars represent the 
mean and range of three independent experiments.   
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Subcellular localization of RL13 in transfected cells 
Stanton et al. recently reported that adenovirus-expressed RL13 transits through the Golgi and 
traffics mainly to Rab5-positive cytoplasmic vesicles [6]. We sought to verify the intracellular 
localization of RL13 expressed transiently in human cells. Confocal microscopy images were collected 
from epithelial (ARPE-19) and fibroblast (MRC-5) cells transfected with two different constructs, the 
previously described myc-His tagged construct and a second construct coding for RL13 with a C-
terminal YFP-tag. Since sub-cellular localization of RL13 with different tags was identical in both cell 
types (data not shown), only representative data obtained in ARPE-19 human epithelial cells with 
RL13-YFP are shown. 
48 h after transfection, cells were fixed, permeabilized and stained with different markers of 
cellular compartments and with fluorophore-conjugated Fcγ. The confocal microscopy analysis of these 
samples is shown in Fig. 4A. RL13 co-localized to a limited extent with Golgi markers and EEA1-
positive endosomes and more extensively with markers of the trans-Golgi network (TGN) (Fig. 4A, left 
panels). Fcγ co-localized extensively with RL13 (Fig. 4A, far right panels), although a population of 
RL13 that does not bind to the Fc of human IgGs was consistently observed (Fig. 4A, green color in far 
right panels). Although it is tempting to speculate that this pool represents an immature ER population, 
also suggested by the shape of the RL13 distribution, we have been unable to find any co-localization 
of RL13 with the ER marker PDI (not shown).  
The presence of RL13 on the surface of both HEK293T and ARPE-19 cells was further verified by 
the use of a mouse monoclonal antibody (mAb 5H3/B10) directed against the ectodomain portion of 
RL13. Analysis by flow cytometry was performed on transiently transfected non-permeabilized 
HEK293T cells (Fig. 4B). A clear increase in fluorescence was obtained on RL13 expressing cells 
stained with mAb 5H3/B10 compared to mock transfected cells or isotype control. Confocal 
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microscopy analysis of non-permeabilized RL13 expressing ARPE-19 cells stained with both Fcγ and 
5H3/B10 revealed a strong accumulation of RL13 on plasma membrane clusters (Fig. 4C) that 
extensively overlapped with Fcγ signals (Fig. 4C, white color in right merge panel).  
These observations are consistent with RL13 trafficking through the secretory pathway and 
recycling from the plasma membrane, although other possible explanations for this pattern have not 
been excluded.  
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Figure 4: Localization of RL13 in transfected cells. 
A: Co-localization of RL13 with organelle markers and Fcγ in ARPE-19 cells. ARPE-19 epithelial 
cells were transfected with RL13-YFP fusion protein (green color, central column) and treated for 
confocal analysis 48 h later. Cells were fixed, permeabilized and stained with antibodies against either 
GM130, TGN46 or EEA1 intracellular markers (red color, second column) and with 20 μg/ml of 
DyLight 649-conjugated human IgG Fc fragment (magenta color, fourth column). The merged panels 
on the far left show co-localization between RL13 and, from top to bottom, markers of Golgi (GM130), 
trans-Golgi (TGN46) and early endosomes (EEA1) respectively (co-localization in yellow). The 
merged panels on the far right show co-localization of Fcγ with RL13 (co-localization in white). 
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B: Flow cytometry analysis of RL13 surface-expression. HEK293T cells were transiently transfected 
with vector coding for YFP (green line) or RL13-YFP fusion protein (red and blue lines). Cells were 
allowed to recover for 48 h and then surface-exposed RL13 was stained either with 5 μg/ml of mouse 
monoclonal antibody directed against RL13 ectodomain (clone 5H3/B10, red and green lines) or 
isotype control at the same concentration (isotype, blue line) on ice. Alexa fluor 647 conjugated goat 
anti-mouse was used as secondary antibody. YFP positive cells were compared to empty vector 
transfected cells for their ability to bind 5H3/B10 antibody. 
C: Immunofluorescence analysis of RL13 surface expression on ARPE-19 cells. ARPE-19 cells 
expressing RL13-YFP fusion protein (red color) were stained on ice with 12.5 μg/ml of 5H3/B10 
monoclonal antibody (green color) and 20 μg/ml of DyLight 649-conjugated human IgG Fc fragment 
(magenta color) without permeabilization. Merge panels show co-localization between 5H3/B10 and 
either RL13-YFP or Fcγ signals (yellow color in the far left panel and white color in the far right panel, 
respectively).  
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Internalization of RL13-Fcγ complex 
The presence of an internalization motif in the C-terminal tail, together with the intracellular 
localization data in Fig. 4, suggested that RL13 could traffic to the cell surface where it may bind and 
internalize extracellular IgGs. To test this hypothesis, we performed a short time-course 
characterization of the internalization of YFP-tagged RL13 in transfected ARPE-19 cells. Cells were 
initially placed on ice to reduce lateral diffusion of membrane proteins and block potential 
internalization of the ligand. Fluorescently labelled Fcγ was added and allowed to bind for 30 min on 
ice. Following extensive washing of the Fcγ excess and fixation of the cells, fluorescence analysis at 
time 0 showed that RL13 partially co-localized with Fcγ on the surface of transfected cells (Fig. 5A). 
Restoring the internalization processes at 37°C induced the uptake of the RL13- Fcγ complex, the 
majority of which accumulated mostly in large ring-shaped structures after 30 min (Fig. 5B). These 
RL13-Fcγ structures persisted 90 min after the shift to 37°C and stained positive for the early 
endosome marker Rab5 (Fig. 5C). 
These data demonstrate that RL13 binds to the Fc of human IgGs on the cell surface and that the 
internalized complex remains associated with large membranous vesicles containing markers of early 
endosomes. 
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Figure 5: RL13 binds and internalizes Fcγ.  
ARPE-19 epithelial cells were transfected with RL13-YFP (green) and allowed to recover for 48 h. 
Cells were placed on ice 5 min before adding DyLight 649-conjugated human IgG Fc fragment (red) 
and incubated on ice for 30 min. Then, cells were washed and A: immediately fixed, B: shifted to 37°C 
for 30 min, or C: shifted to 37°C for 90 min before proceeding to fixation and confocal analysis. Rab5 
(purple) was revealed by specific antibodies after permeabilization of the samples. Examples of co-
localization between signals are indicated by white arrows. Orthogonal projections of the optical 
sections acquired from Z-stack are shown. White arrows indicate examples of co-localized spots. 
Fluorescent Fcγ was absent on the membrane of ARPE-19 cells transfected with empty expression 
vector used as control and no staining was detected following 30 min switch at 37°C (data not shown).   
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Mutation of RL13 sorting motif affects the internalization of Fcγ 
As shown by the in silico analysis, the carboxy-terminal domain of RL13 contains a tyrosine-based 
sorting signal (YxxL282) that could be responsible for the internalization of the RL13-Fcγ complex. A 
local multiple sequence alignment of the C-terminal region of RL13 from 15 HCMV strains showed 
that the YxxL motif was highly conserved (Fig. 6A, residues 279-282). To test the contribution of the 
cytoplasmic tail, and in particular of the tyrosine motif, to the internalization of the RL13-Fcγ complex, 
a panel of mutants were built (Fig. 6B). Plasmids encoding RL13 with three single amino acid 
substitution mutants, Y279F, Y279A, T280A, one double substitution mutant Y279A/L282A 
(indicated as AA), one triple substitution mutant Y279A/R281A/L282A (AAA), and one quadruple 
substitution mutant with all amino acids of the motif replaced by alanines (AAAA) were produced. 
Additionally, plasmids encoding a YxxL deletion mutant (Δ279-282), a deletion of the motif and the 
entire C-terminal (Δ279-294), and a deletion of 12 amino acids immediately C-terminal to the sorting 
motif (Δ283-294) were generated. 48 h after transfection, internalization of the mutated/deleted 
proteins was assessed by flow cytometry on HEK293T cells incubated with Fcγ at 4°C for 30 min and, 
after removal of the ligand by extensive washing, shifted to 37°C. The percent of internalized Fcγ was 
calculated from the mean fluorescence intensity of the samples incubated at 37°C for 30 minutes and 
the samples submitted to the same treatment but kept on ice. As shown in Fig. 6C, the YxxL motif is 
critical for protein internalization since removing the region downstream did not alter the RL13 Fcγ 
internalization ability while deletion of the motif, both individually or with the C-terminus sequence, 
strongly reduced the internalization ability of RL13 (Fig. 6C). Substitution of the tyrosine 279 with 
phenylalanine, an alternative aromatic side chain, did not reduce the ability of RL13 to internalize. In 
contrast, uptake was reduced by approximately 1/3 when an alanine was placed in this position. 
Substitution of the adjacent threonine 280 with alanine did not show a difference in internalization 
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compared to the wild type. However, leucine 282 appeared to play a role as shown by the further 
internalization reduction of the Y279/L282 double mutant (Fig. 6C). Substitution of multiple residues 
with alanine reduced internalization to the same extent as complete deletion of the YxxL motif (Fig. 
6C).  
Taken together these results are consistent with the YxxL282 motif being necessary for Fcγ 
internalization by RL13 and suggest that an aromatic residue at position 279 is required.  
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Figure 6: RL13 C-terminal YxxL motif is required for internalization. 
A: Local multiple sequence alignment of the RL13 C-terminus. The gray box indicates the 
transmembrane domain, the black box the YxxL internalization motif. Darker color indicates higher 
conservation. Asterisks (*) below the alignments represent conserved amino acid in all sequences; 
colons (:) represent residues with similar physicochemical properties; dots (.) semi-conserved residues.  
B: Graphical representation of RL13 mutations used in this study. RL13 TR cytoplasmic tail 
sequence is shown with mutated amino acids in bold. Amino acids unchanged from the wild-type 
sequence are represented by a dot. Deleted amino acids are represented by a |. 
C: Internalization efficiency of RL13 variants. HEK293T cells were transfected with the indicated 
plasmids coding for wild type and mutated RL13. 48 h post-transfection, cells were detached and 
incubated on ice for 60 min with human Fc fragment. Cells were then washed and incubated in 
medium at 37°C for 30 min to allow for endocytosis (T37). The control sample remained on ice (T0). 
Following incubation, cells were cooled quickly by rinsing twice with cold PBS; Fc that remained on 
the cell surface after endocytosis was stained with Alexa Fluor 647-conjugated goat anti-human IgG 
and analyzed by flow cytometry. The % of internalization was calculated from the mean fluorescence 
intensities of transfected cells with the following formula: (T0−T37)/T0×100%. Value retrieved from 
RL13 wild type was set to 100%. Values are the mean and range of three independent experiments. 
Significant differences, P<0,001 (two-tailed unpaired Student’s t-test), compared to RL13 are indicated 
by *.  
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Fcγ binding ability is conserved in the HCMV Merlin strain 
Due to the high variability of the RL13 genes among different HCMV strains [20] we also tested 
the Merlin RL13 protein (87% aa identity with its TR counterpart) for its Fcγ binding ability. In vitro 
synthesized Merlin RL13 gene was cloned in pcDNA3.1(-)/myc-His expression vector and used to 
transfect HEK293T cells. Intracellular staining was performed as previously described and cells were 
analyzed through flow cytometry. Both the expression levels (data not shown) and the Fcγ binding 
ability of cells expressing RL13 from Merlin and TR strains were comparable (Fig. 7A). To further 
confirm the specificity of the binding, both proteins were immunoprecipitated from transfected cell 
lysates with biotinylated Fcγ. Complexes were captured with magnetic streptavidin beads and eluted 
material was separated by SDS-PAGE and analyzed by immunoblot using anti-tag and anti-human IgG 
antibodies (Fig. 7B). Both Merlin and TR RL13 proteins were successfully immunoprecipitated from 
cell lysates. The observed molecular weights of the two proteins in denaturing and reducing conditions 
appeared to be slightly different: TR RL13 was composed of three major isoforms of around 123 kDa, 
111 kDa and 76 to 66 kDa, while Merlin RL13 gave three bands of 116 kDa, 108 kDa and 66 to 52 kDa. 
These differences in the molecular weight could reflect the different glycosylation profiles, with 7 and 
11 predicted N-linked glycosylations for RL13 from Merlin and TR strains, respectively.  
These experiments support the conclusion that the Fc-binding ability of RL13 is conserved in at 
least two different clinical HCMV isolates. 
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Figure 7: Fc binding is a conserved function for recombinant RL13 from Merlin and TR clinical 
strains. 
A: HEK293T cells were transfected with plasmids coding for myc-His tagged RL13 from TR (red), 
Merlin (blue) strains and empty vector (green). 48 h post-transfection cells were collected, 
permeabilized and stained with FITC-conjugated mouse anti-myc and 25 μg/ml of DyLight 649-
conjugated human IgG Fc fragment. 10,000 FITC-positive cells were compared to empty vector 
transfected cells.  
B: HEK293T cells were transfected with empty vector or plasmids coding for myc-His tagged RL13 
from TR and Merlin strains. 48 h post-transfection cells were collected, lysed and subjected to 
immunoprecipitation with biotinylated Fc fragment. Total lysates and elution fractions were subjected 
to western blot analysis using HRP-conjugated anti-his tag (α-his) and anti-human IgG (α-h) antibodies. 
TR: sample expressing myc-His tagged RL13 from TR strain; Merlin: sample expressing myc-His 
tagged RL13 from Merlin strain; Empty: empty vector transfected cells.  
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DISCUSSION 
The low fitness of wild-type RL13-carrying strains cultured in vitro, leading to the destruction of 
the ORF present in the clinical isolates within a few passages [5,6], make functional studies of this 
protein difficult. To better understand its function, we used synthetic RL13 genes reproducing the 
sequences of the clinical isolates TR and Merlin. In the absence of an unpassaged reference sample of 
TR, we cannot say with certainty that the sequence and function of the TR RL13 we used is identical to 
the originally isolated, naturally occurring virus. However, we do not detect functional differences 
between RL13 from the TR and Merlin strains. Expression of this recombinant protein in human-
derived epithelial cells allowed us to demonstrate that RL13: a) binds Fc from IgG of human (and 
rabbit) origin; b) preferentially binds to Fc from IgG1 and IgG2 subclasses; c) is at least transiently 
exposed on the cell surface and is subsequently internalized with (and likely without) bound Fcγ; d) 
internalization relies on a YxxL motif and e) its Ig-like extracellular domain is necessary for Fcγ 
binding. Similar analysis of RL13 in human fibroblasts produced identical results (data not shown). 
Furthermore, we revealed that RL12 also binds IgG1 and IgG2, although we did not study this 
interaction in detail. Our data does not offer an explanation for why RL13 is so rapidly mutated when 
clinical isolates of HCMV are grown in cultured cells [5].  
Apart from HCMV, viral Fcγ binding proteins (vFcBPs) are present on herpes simplex virus type 1 
(HSV-1), HSV-2, and varicella zoster virus and on the non-human herpesviruses pseudorabies virus 
and murine cytomegalovirus [21–25]. The most accepted model to explain how those activities promote 
immune evasion is the so called “antibody bipolar bridging” in which the neutralizing potential of the 
IgG Fab domain is counteracted by simultaneous binding of vFcBPs to the Fc domain of the same 
immunoglobulin molecule [26,27]. The possibility of this mechanism has been supported at a 
molecular level by Sprague and coworkers [27], who crystallized a portion of HSV gE ectodomain and 
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gE-gI complex bound to an human IgG Fc fragment. Alternatively, it has been hypothesized that HSV, 
as well as HCMV vFcBPs, function once expressed on infected cell surface by endocytosis and 
subsequent degradation of complexes including human IgG and viral antigens [11,27]. Consistent with 
this hypothesis, we observed that RL13 is able to internalize human IgG Fc fragment from the surface 
of transfected cells trafficking at early times in Rab5 and EEA1 positive endosomes. The well-
recognized YxxL motif is essential for RL13 endocytosis through the aromatic nature of the tyrosine 
and not its property of phosphate acceptor. As already described for the RID receptor of adenovirus 
[28], this type of sorting signal does not affect signal transduction pathways. On the other hand, the fact 
that RL13 is located on the envelope of the virus [6] suggests that antibody bipolar bridging could be an 
important function of RL13 that would help protect HCMV virions from complement- and antibody-
dependent neutralization.  
RL13 and RL12 discriminate among human IgG subtypes showing no association with IgG3 and 
IgG4. To our knowledge, this observation remains the only example of vFcBPs selecting not only 
among immunoglobulin isotypes but also IgG subtypes. IgG2 represents roughly 25% of human total 
plasma IgGs in adults and has been traditionally associated with protection from infection with 
encapsulated bacteria since their immune function is primarily directed against polysaccharide antigens 
[29]. Recent reports, however, have pointed out a significant association between IgG2 deficiency and 
severe or even fatal clinical outcome of the pandemic influenza A (H1N1), although IgG2 unbalance 
has been suggested to be a consequence of cytokine deregulation rather than a predisposing risk factor 
[30,31]. Due to the low number of studies performed on human IgG2 function related to viral infection, 
the meaning of such observation remains elusive and needs further analysis. Compared to IgG1, 
subtype 2 immunoglobulins cannot mediate complement-dependent cytotoxicity or NK-mediated 
antibody-dependent cellular cytotoxicity (ADCC) but do engage FcγRIIa receptors and trigger ADCC 
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mediated by cells of the myeloid lineage [32]. Again, the relative importance of IgG2 subtype in 
protecting from viral infection just begun to be addressed and it is difficult to evaluate the importance 
of a viral factor able to counteract such mechanism, if any, but it is noteworthy that HCMV has a latent 
reservoir in myeloid cells [33]. It is tempting to speculate that a viral IgG2-binding receptor could 
compete with cellular receptors for binding to cellular antibodies to viral proteins and prevent ADCC. 
It would be important to determine the affinity of RL13, as well as of the other HCMV Fcγ binding 
proteins, toward IgG2 to evaluate if this protein represents a function more dedicated to a particular 
IgG subtype.  
Atalay and coworkers described the presence of immunoglobulin supergene family (IgSF)-like 
domains in the products of both RL11 and UL119 genes [11]. We have mapped the RL13 Fcγ binding 
activity to the Ig-like domain in the extracellular region, while the N-terminal proximal region 
composed of approximately 70 amino acids is not crucial for the binding. Indeed, Sprague et al. 
showed that removing the N-terminal part of the gp68 ectodomain did not impair the Fc binding [13]. 
These data are consistent with the presence of an immunoglobulin supergene family (IgSF)-like 
domains in all the described HCMV Fc binding proteins. Our findings do not rule out the possibility 
that RL13 could carry out other functions. The best characterized viral Fc binding protein, the gE 
product of HSV-1, is also involved in cell-to-cell spread or trafficking of viral proteins from neuron 
body cell into axon independently of its Fc binding capability [34,35]. We are currently investigating 
other possible roles of RL13 during HCMV pathogenesis.  
Our preliminary characterization of transiently transfected RL13 agrees only partially with what 
was reported by Stanton et al. [6]. They found significant differences in cellular localization and 
apparent SDS-PAGE MW between adenovirus-expressed RL13 and the protein expressed in the 
context of viral infection. In their report, adenovirus-expressed RL13 showed a lower MW (80 and 55 
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kDa) compared to the species found in infected cells (100 and 55 kDa) and the protein only co-
localized with TGN in the context of infection [6]. The behavior of RL13 observed in this report is 
more similar to Stanton et al.’s data for infected cells, showing a MW above 100 kDa and a sub-
cellular co-localization with early endosomes and the TGN. This last observation would be consistent 
with a default mechanism of internalization similar to what was described for other HCMV envelope 
proteins [36]. We currently have no explanation for the slight discrepancies between Stanton et al. and 
our report that may be due to the different expression system used or, at least for the confocal analysis, 
to the protein derived from a different strain. However, characterization of the expressed RL13 remains 
preliminary and further studies will elucidate this point. 
To conclude, we have shown that RL13 encoded by HCMV TR binds the Fc portion of human 
IgG1 and IgG2 and propose that this protein is used by the virus to circumvent the humoral immune 
response in the host.  
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MATERIALS & METHODS 
Sequence data, in silico analysis and predictions 
Start to stop open reading frames (ORFs) in the complete genome sequence of the TR strain 
(Genbank: AC146906.1) were identified using the Getorf program from the EMBOSS suite 5.0.0 [37]. 
The sequence similarity searching algorithm FASTA 35.4.3 [38]. was exploited to compare the protein 
sequences of RL13 gene product from the Merlin strain (Genbank: YP_081461.1) to all the TR ORFs 
and select homologous ones with BLOSUM50 as substitution matrix and imposing an expectation 
value (E) upper limit of 1e-05. The putative TR RL13 sequence was searched for specific conserved 
signatures using InterProScan 4.8 [39] with databases v.34.0. Multiple sequence alignments were 
performed using the PSI-Coffee mode of T-Coffee v.9.01 [40], comparing the TR RL13 with an 
additional 14 different RL13 protein sequences (Genbank: YP_081461.1, AEI84615.1, ACS91939.1, 
AAR31271.1, AAR31220.1, ACT81850.1, ACT81685.1, ACS92104.1, ACZ79760.1, ACZ79925.1, 
ADI46773.1, ACZ80255.1, ABV71530.1, ACZ80090.1). Signal peptides and transmembrane regions 
were predicted by Phobius [41], while secondary structures were predicted using PSIPRED [42]. N-
linked and O-linked glycosylation sites were predicted using NetNGlyc 1.0 
(http://www.cbs.dtu.dk/services/NetNGlyc/) and NetOGlyc 3.1 [43] 
(http://www.cbs.dtu.dk/services/NetOGlyc/) respectively. 
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Cells, plasmids and antibodies 
ARPE-19, MRC-5 and HEK293T cell lines were brought from ATCC and cultured according to 
the supplier’s instructions. DMEM high glucose and DMEM:F12 media (Gibco, Invitrogen) were 
supplemented with 10% fetal calf serum (FCS) and penicillin streptomycin glutamine (Gibco, 
Invitrogen). Lipofectamine 2000 (Invitrogen) was used to transfect HEK293T cells while Fugene 6 
(Roche) and Nucleofector kit V (Amaxa) were used to transfect ARPE-19 cells as suggested by 
manufacturer. Human codon-optimized RL10, RL11, RL12, RL13 and gB (UL55) HCMV genes based 
on the TR strain sequence and RL13 from Merlin strain (NCBI Reference Sequence: YP_081461.1) 
were synthesized by Geneart and cloned in plasmid pcDNA3.1(-)/myc-His C (Invitrogen) in frame with 
C-terminal myc and six histidine tag sequences. Fluorescent fusion proteins were obtained by 
subcloning a gene of interest upstream of the EYFP sequence in pEYFP-N1 vector (Clontech). 
Ectodomain and C-terminal tail RL13 mutants were cloned using QuickChange™ Site-directed 
Mutagenesis kit and instructions therein (Stratagene). Primary antibodies used in this work were mouse 
anti-His (C-term) and mouse anti-PDI (Invitrogen), mouse anti-Rab5 mouse, anti-GM130, mouse anti-
TGN46 and mouse anti-EEA1 (Abcam). Mouse monoclonal antibody against RL13, clone 5H3/B10, 
was developed by Areta International (Gerenzano, Italy). Mice immunization was performed with 
peptides encompassing the amino acid region 111-246 of TR strain RL13. Secondary antibodies were 
Alexa Fluor 488-, 568-, and 647-conjugated goat anti-mouse (Invitrogen) and HRP-conjugated 
secondary antibodies from Perkin Elmer. Chrompure DyLight 649-conjugated rat, rabbit, mouse, goat 
IgG and human Fc fragment were from Jackson Immunoresearch, human IgG subclasses from SIGMA, 
and human IgA, IgE, IgM from Calbiochem.  
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Flow cytometry 
For intracellular staining, HEK293T cells transfected with the plasmids of interest were trypsin 
detached 48 h post-transfection, incubated 30 min at RT with Live&Dead Agua (Invitrogen), diluted 
1:400 in PBS, fixed and permeabilized with Cytofix/Cytoperm kit (BD) and stained as instructed by the 
manufacturer. For cells expressing the myc-tagged proteins, mouse anti-myc-FITC antibody was used 
at 1:500 dilution. Binding of the Fc portion of the human IgGs (Fcγ) was assessed using DyLight 649-
conjugated human IgG Fc fragment or different human immunoglobulin isotypes and human IgG 
subclasses at different concentrations (5-50 μg/ml). Alexa Fluor 647 fluorophore-conjugated secondary 
antibodies against the above mentioned species were used at 1:200 dilution. For membrane staining, 
transfected cells were detached with trypsin 48 h post-transfection and incubated for 30 min on ice with 
DyLight 649-conjugated human Fcγ. When needed, cells were subsequently subjected to intracellular 
staining. A total of 10
4
 cells were analyzed for each histogram using FACSCanto II (Becton Dickinson, 
Heidelberg, Germany). For detection of membrane exposed RL13, HEK293T were transiently 
transfected with vectors coding for YFP or RL13-YFP fusion protein, were incubated with different 
dilutions of mouse monoclonal 5H3/B10 antibody or mouse IgG1 isotype control (Sigma) for 60 min 
on ice. As secondary antibody, Alexa Fluor 647-conjugated goat anti-mouse was used for 30 min on ice 
at 1:200 dilution. Internalization of Fcγ in HEK293T cells was quantified through flow cytometry. 48 h 
post-transfection cells were detached with trypsin and transferred to round bottom 96 well plates for 
staining. Cells were washed in cold PBS and incubated on ice with human IgG Fc fragment at different 
concentrations (50, 25, 12.5 μg/ml). After 30 min incubation, cells were extensively washed and 
incubated with warm medium to allow for endocytosis (Fcγ37°C). Half of the samples were kept on ice 
for the duration of the experiment (Fcγ4°C). At the end of the endocytosis, cells were washed with cold 
medium and Fcγ remaining on the surface was stained with Alexa fluor 488 conjugated goat anti-
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human antibody. The percentage of internalized Fcγ was calculated as: (Fcγ4°C - Fcγ37°C)/Fcγ4°C x 100. 
Values shown are relative based on internalization by RL13 wild type. 
 
Confocal microscopy analysis 
Cells transfected with plasmids of interest were trypsin detached and plated on glass coverslips for 
24 h post transfection. For intracellular staining, cells were fixed 48 h post transfection with 3.7% 
paraformaldehyde, permeabilized with 0.1% Triton X-100 (Sigma), blocked with PBS with 1% BSA 
and stained at RT by incubating for 1 h with primary antibodies in PBS/1% BSA, washed in PBS, and 
further incubated with secondary antibodies in PBS/1% BSA for 1 h. The ProLong Gold with DAPI 
(Invitrogen) was used as mounting solution. For membrane staining, the permeabilization step was 
omitted and fixation was performed after staining with primary and secondary antibodies for 30 min on 
ice. For human Fcγ internalization, cells expressing RL13-YFP, YFP, or empty vector (controls) were 
plated on glass coverslips 24h post transfection. 24 h later, cells were washed in cold PBS and 
incubated at 4°C with 20 μg/ml of DyLight 649-conjugated human Fcγ for 30 minutes. After extensive 
washes, temperature was switched to 37°C to allow for internalization. When required, cells were fixed, 
permeabilized and stained before mounting. The intracellular locations of antibody-tagged or 
fluorescent fusion proteins were examined under laser illumination in a Zeiss LMS 710 confocal 
microscope and images were captured using ZEN software (Carl Zeiss). 
 
Immunoprecipitation 
HEK293T cells were transfected with empty vector or myc-His tagged RL13 from TR or Merlin 
strains. 48 h post-transfection, cells were harvested, washed in cold PBS several times and lysed in 
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lysis buffer (25 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% glycerol, 1 mM EDTA) containing 1% NP-
40 (Roche) and supplemented with complete EDTA-free protease inhibitors (Roche). Supernatants 
were collected after centrifugation at max speed for 30 min at 4°C in a tabletop centrifuge. 100 µg of 
lysate was incubated with 2 μg of biotinylated human IgG Fc fragment (Jackson immunoresearch) for 1 
h at 4°C, then with 30 μl of Streptavidin Dynabeads (Invitrogen) prewashed in lysis buffer. 
Precipitation was carried out at 4°C with overnight rotation. Immunocomplexes were collected using 
magnetic beads, washed 4 times with lysis buffer and eluted by adding 30 µl of LDS-buffer and heating 
at 96°C for 5 minutes. Lysates were mixed with 100 mM DTT (Sigma) and heated at 96°C for 3 min. 
Proteins were then separated by SDS-PAGE and blotted on a nitrocellulose membrane. Membranes 
were blocked in blocking buffer (5% w/v nonfat dry milk in PBS with 0.1% Tween 20). All 
incubations with antibodies were done at room temperature for 1 h in blocking buffer. Mouse anti-His 
(Invitrogen) was used at 1:1,000 dilution. Secondary antibodies were diluted 1:10,000 in blocking 
buffer.   
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